January | February | March | April | May | June | July | August | September | October | November | December |
|
Deal title | Principal company | Partner company | Value (US$M) | Start date |
Cancer Research UK to conduct phase IIa clinical study of Bicycle Therapeutics' BT-7401 against cancer | Cancer Research UK | Bicycle Therapeutics plc | Payment unspecified | 1/7/20 |
Ervaxx and Cardiff University to develop T-cell and TCR based immunotherapeutics targeting dark antigens for cancer | Cardiff University | Ervaxx | Payment unspecified | 1/24/20 |
Oncotartis and Children's Cancer Institute to study discovery, mechanism of action, toxicological profile and preclinical efficacy of OT-82 against leukemia | Children's Cancer Institute Australia for Medical Research | Oncotartis Inc. | Payment unspecified | 1/16/20 |
Pear Therapeutics to use Cincinnati Children’s Hospital Medical Center’s clinical-stage digital therapeutic to treat migraine headaches | Cincinnati Children's Hospital Medical Center | Pear Therapeutics Inc. | Payment unspecified | 1/7/20 |
Distributed Bio to use Superhuman antibody technology to discover and optimize therapeutics against Washington University's targets | Distributed Bio | Washington University School of Medicine, US | Payment unspecified | 1/14/20 |
Dongfang hospital to initiate a project and conduct research on a Stemirna's mRNA COVID-19 vaccine | Dongfang Hospital | Tongji University | Payment unspecified | 1/28/20 |
Bloom Science to Duke's heirloom strain therapeutics for Akkermansia bacterial infection using microbiome technology | Duke University | Bloom Science Inc. | Payment unspecified | 1/15/20 |
Hoth Therapeutics exercised its option to license for patents owned by George Washington University (GW) after evaluating GW's formulations of aprepitant | George Washington University | Hoth Therapeutics Inc. | Payment unspecified | 1/15/20 |
Gladstone and Genentech to test the efficacy of GNE-0723 in mouse models of Alzheimer's disease and Dravet syndrome | Gladstone Institute of Neurological Disease | Genentech Inc. | Payment unspecified | 1/14/20 |
Bill & Melinda Gates MRI to develop GSK's M72/AS-01 against lung tuberculosis | Glaxosmithkline plc | Bill & Melinda Gates Medical Research Institute | Payment unspecified | 1/27/20 |
ANP Technologies Inc. and Fulgent Pharma LLC through their partner Moffitt Cancer Center licensed rights of leukemia therapies to Celgene | H Lee Moffitt Cancer Center and Research Institute | Celgene Corp. | Payment unspecified | 1/10/20 |
Hadasit to conduct preclinical studies of Canonic's medical cannabis products for inflammation and pain management | Hadassah Medical Organization | Canonic Ltd. | Payment unspecified | 1/27/20 |
Onxeo and Gustave Roussy to conduct phase Ib/II study of Asidna on niraparib for relapsed ovarian cancer | Institut Gustave Roussy | Onxeo SA | Payment unspecified | 1/29/20 |
Chongqing Zhifei Biological and Institute of Microbiology to develop recombinant protein subunit vaccine for coronavirus infection | Institute of Microbiology, CAS | Chongqing Zhifei Biological Products Co. Ltd. | Payment unspecified | 1/29/20 |
Pear Therapeutics to license content for a clinical-stage digital therapeutic from Karolinska Institute’s researchers to treat irritable bowel syndrome | Karolinska Institutet | Pear Therapeutics Inc. | Payment unspecified | 1/7/20 |
MDC and Plasmidfactory to develop gene therapy for cancer using Sleeping Beauty 100x | Max Delbruck Centrum Fur Molekulare Medizin | Plasmidfactory GmbH & Co KG | Payment unspecified | 1/16/20 |
MD Anderson Cancer Center to manufacture Bellicum's Gocar and other cellular therapy programs | MD Anderson Cancer Center | Bellicum Pharmaceuticals Inc. | Payment unspecified | 1/21/20 |
Angiogenex and MSKCC to develop and commercialize series of anti-ID compounds against liver cancer worldwide | Memorial Sloan-Kettering Cancer Center | Angiogenex Inc. | $7.33 | 1/28/20 |
Tacitus to develop Mount Sinai's hematopoietic stem cell therapies for blood cancers and related clotting disorders | Mount Sinai Health System | Tacitus Therapeutics Inc. | Payment unspecified | 1/9/20 |
Opiant and NCATS to enter a letter of intent for development of OPNT-004 against acute cannabinoid overdose | National Center For Advancing Translational Sciences | Opiant Pharmaceuticals Inc. | Payment unspecified | 1/2/20 |
NIAID to design and conduct IND-enabling studies and a phase I clinical study in the U.S. on Moderna's mRNA vaccine against the 2019-nCoV | National Institute of Allergy and Infectious Diseases | Moderna Therapeutics | Payment unspecified | 1/23/20 |
National Institutes of Health and Axovant to study characterizing the natural history of Type 1 GM1 gangliosidosis in molecular genetics and metabolism | National Institutes of Health | Axovant Gene Therapies Ltd. | Payment unspecified | 1/13/20 |
Northshore University to study Eagle’s Ryanodex for concussion and other forms of traumatic brain injury in animal models | Northshore University Healthsystem | Eagle Pharmaceuticals Inc. | Payment unspecified | 1/6/20 |
NHS England to sign a memorandum of understanding with Novartis to develop inclisiran for the treatment of atherosclerosis in the U.K. | Novartis AG | National Health Service | Payment unspecified | 1/13/20 |
Sino Biological and Peking University to develop SARS-CoV-2 neutralizing antibodies against COVID-19 | Peking University | Sino Biological Inc. | Payment unspecified | 1/27/20 |
Quantumleap to evaluate G1 Therapeutics' trilaciclib against breast cancers | Quantum Leap Healthcare Collaborative | G1 Therapeutics Inc. | Payment unspecified | 1/14/20 |
Gilead Sciences to develop and commercialize Rockefeller University's broadly neutralizing antibodies against HIV, including 3BNC-117 and 10-1074 worldwide | Rockefeller University | Gilead Sciences Inc. | Payment unspecified | 1/9/20 |
Decibel to develop Rockefeller University's series of small-molecule LATS inhibitors for hearing and balance disorders worldwide | Rockefeller University | Decibel Therapeutics | Payment unspecified | 1/29/20 |
Horizon Discovery Group exercised its option to exclusively license Rutgers University’s base-editing technology for therapeutic, diagnostic and service applications | Rutgers University | Horizon Discovery Group plc | Payment unspecified | 1/14/20 |
Calibr and Cystic Fibrosis Foundation to identify existing medicinal compounds that show efficacy against one of the hardest-to-treat infections for patients with cystic fibrosis | Scripps Research Institute | Cystic Fibrosis Foundation | Payment unspecified | 1/14/20 |
Sapphire Biotech to use Skysong's intellectual property related to pharmaceutical compositions and methods for cancer treatments | Skysong Innovations LLC | Sapphire Biotech Inc. | Payment unspecified | 1/22/20 |
NYSCF and Cytovia Therapeutics to develop precision gene edited induced pluripotent stem cell-derived natural killer and CAR NK therapeutics for cancers | The New York Stem Cell Foundation | Cytovia Therapeutics Inc. | Payment unspecified | 1/9/20 |
Titan Pharmaceuticals to supply Probuphine for US veterans to treat opioid use disorder | Titan Pharmaceuticals Inc. | U.S. Department of Veterans Affairs | Payment unspecified | 1/13/20 |
Gene Techno Science and Tokyo Metropolitan Institute to research and develop therapeutic treatments for cerebral palsy | Tokyoto Igaku Kenkyu Kiko | Gene Techno Science Co. Ltd. | Payment unspecified | 1/22/20 |
Microcures and USAISR to enter CRADA to advance siFi2 for healing of burn wounds | United States Army Institute of Surgical Research | Microcures Inc. | $1.00 | 1/28/20 |
Medigene and UdeM to study, develop and commercialize TCRs against up to 5 of the cancer antigens for immunotherapies worldwide | Universite De Montreal | Medigene AG | Payment unspecified | 1/29/20 |
Dinaqor and UCL to develop gene therapies for the treatment of monogenic cardiomyopathies worldwide | University College London | Dinaqor AG | Payment unspecified | 1/13/20 |
Diomics and University of California to improve islet transplantation for patients living with type 1 diabetes | University of California | Diomics Corp. | Payment unspecified | 1/2/20 |
University of California to evaluate Actinium's ARC apamistamab-I-131 against HIV related lymphoma patients | University of California Davis | Actinium Pharmaceuticals Inc. | Payment unspecified | 1/13/20 |
Orion Biotechnology to use University of Geneva's drug discovery platform to develop GPCR chemokine analogs worldwide | University of Geneva | Orion Biotechnology Canada Ltd. | Payment unspecified | 1/21/20 |
Hoth Therapeutics exercised its option for full licensing rights to develop and commercialize therapeutic compounds for the treatment of dermatological conditions with the University of Maryland, Baltimore and Isoprene Pharmaceuticals | University of Maryland, Baltimore | Hoth Therapeutics Inc. | Payment unspecified | 1/29/20 |
University of Saskatchewan and Zyus to conduct cannabinoid-based research for brain disorders | University of Saskatchewan | Zyus Life Sciences Inc. | Payment unspecified | 1/7/20 |
U.S. Department of Defense exercised an option to purchase 80,000 additional doses of Valneva's Ixiaro | Valneva SE | U.S. Department of Defense | Payment unspecified | 1/15/20 |
Yposkesi to produce Genethon's AAV8-Spc5.12 gene therapy for Duchenne muscular dystrophy | Yposkesi SAS | Genethon | Payment unspecified | 1/9/20 |
Advent to manufacture Jenner Institute's ChAdOx1 nCoV-19 vaccine against coronavirus infection | Advent Srl | The Jenner Institute | Payment unspecified | 2/10/20 |
Sapphire Biotech and ASU to conduct preclinical studies using quiescin sulfhydryl oxidase 1 as anti-neoplastic compounds | Arizona State University | Sapphire Biotech Inc. | Payment unspecified | 2/10/20 |
Biomarin and ARUP laboratories to develop companion diagnostic for valoctocogene roxaparvovec in hemophilia A patients | ARUP Laboratories | Biomarin Pharmaceutical Inc. | Payment unspecified | 2/20/20 |
VUMC to use Berkeley's Beacon optofluidic platform to screen blood samples for antibodies discovery against coronavirus (COVID-19) in the US | Berkeley Lights Inc. | Vanderbilt University Medical Center | Payment unspecified | 2/28/20 |
University of Queensland to use Berkeley's Beacon optofluidic platform to expedite development of recombinant subunit vaccine program for coronavirus (COVID-19) in Australia | Berkeley Lights Inc. | University of Queensland | Payment unspecified | 2/28/20 |
Beth Israel Deaconess Medical Center and Bioqual to develop in-vivo testing of COVID-19 vaccines in animal model | Beth Israel Deaconess Medical Center | Bioqual Inc. | Payment unspecified | 2/29/20 |
Enterome and Bioaster to develop EO-2463 for against cancer | Bioaster | Enterome SA | Payment unspecified | 2/3/20 |
Children's Memorial Health Institute to conduct phase I clinical trial of CNS Pharma's Berubicin against pediatric brain cancer in Poland | Children's Memorial Health Institute, Poland | CNS Pharmaceuticals Inc. | Payment unspecified | 2/11/20 |
Chugai to supply cancer drugs to National Cancer Center Japan for patient-requested therapy system | Chugai Pharmaceutical Co. Ltd. | Japanese National Cancer Center | Payment unspecified | 2/7/20 |
Abnova to use Chung Yuan Christian University's VLP platform to screen and validate the antibodies including neutralizing antibody against COVID-19 | Chung Yuan Christian University | Abnova (Taiwan) Corp. | Payment unspecified | 2/2/20 |
Dyadic and IIBR expanded their collaboration to combat the COVID-19 virus outbreak with vaccines and monoclonal antibodies developed using C1 gene expression platform | Dyadic International Inc. | Israel Institute for Biological Research | Payment unspecified | 2/25/20 |
University of Rochester and Evgen to advance SFX-01 into a clinical trial against chronic kidney disease | Evgen Pharma plc | University of Rochester | Payment unspecified | 2/13/20 |
Secarna to develop First Affiliated Hospital of Sun Yat-Sen University's ACE2 oligonucleotide antisense therapy for COVID-19 | First Affiliated Hospital of Sun Yat-Sen University | Secarna Pharmaceuticals GmbH & Co KG | $0.43 | 2/21/20 |
Fudan University to screen Coronavirus related pneumonia patients using Active Motif's single-cell Abepic technology | Fudan University | Active Motif LLC | Payment unspecified | 2/26/20 |
Biology Institute of Shandong Academy of Sciences to award a contract to Generex for the development of a COVID-19 vaccine | Generex Biotechnology Corp. | Biology Institute of Shandong Academy of Sciences | $6.00 | 2/27/20 |
German Red Cross to supply Erytech's donor red blood cells to manufacture eryaspase in Europe | German Red Cross Blood Donor Service | Erytech Pharma SA | Payment unspecified | 2/20/20 |
Oncologie and Moffitt Cancer Center to study tumor microenvironment for precision medicine against gastric and gastrointestinal cancers | H Lee Moffitt Cancer Center and Research Institute | Oncologie Inc. | Payment unspecified | 2/25/20 |
Venturis to use JCU's intellectual property rights related to peptide-based technology to develop wound healing approaches | James Cook University of North Queensland | Venturis Therapeutics Inc. | Payment unspecified | 2/25/20 |
BARDA and Janssen to develop coronavirus vaccine against COVID-19 coronavirus | Johnson & Johnson | U.S. Department of Health and Human Services | $456.00 | 2/11/20 |
Cocrystal to use intellectual property rights related to KSURF's antiviral compounds for the treatment of norovirus and coronavirus infections | Kansas State University Research Foundation | Cocrystal Pharma Inc. | $3.20 | 2/12/20 |
Bridge Biotherapeutics acquires Konkuk University's drug development candidate for back-eye disorder treatments | Konkuk University | Bridge Biotherapeutics Inc. | $8.53 | 2/5/20 |
LDC and Leibniz Institute to develop GRK-5 Inhibitors for the treatment of heart failure and cardiac hypertrophy | Leibniz - Institut Für Analytische Wissenschaften - Isas - Ev | Lead Discovery Center GmbH | Payment unspecified | 2/5/20 |
Theratechnologies and Massachusetts General Hospital for the development of tesamorelin against nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in people living with HIV | Massachusetts General Hospital | Theratechnologies Inc. | Payment unspecified | 2/4/20 |
MD Anderson Cancer to conduct research on Berg's ubiquitin-conjugating enzyme modulators against solid tumor and pancreatic cancer | MD Anderson Cancer Center | Berg Pharma LLC | Payment unspecified | 2/27/20 |
INIA and AB-Biotics to develop and commercialize probiotic strains as antimicrobials worldwide | National Institute of Agricultural and Food Technology and Research (INIA) | AB Biotics | Payment unspecified | 2/10/20 |
NIAID to evaluate the safety and efficacy of the Gilead's remdesivir in hospitalized adults diagnosed with COVID-19 | National Institute of Allergy and Infectious Diseases | Gilead Sciences Inc. | Payment unspecified | 2/25/20 |
Innovation to enter material transfer agreement with NIAID's RBLs to evaluate brilacidin against coronavirus infection | National Institute of Allergy and Infectious Diseases | Innovation Pharmaceuticals Inc. | Payment unspecified | 2/27/20 |
Medigen Biotechnology and NIH to develop COVID-19 vaccine | National Institutes of Health | Medigen Biotechnology Corp. | Payment unspecified | 2/16/20 |
Novartis and DNDi to develop oral LXE-408 for visceral leishmaniasis | Novartis AG | Drugs for Neglected Diseases Initiative | Payment unspecified | 2/25/20 |
Ohio State University to conduct clinical trial for Kiadis Pharma' K-NK003 against relapsed/refractory acute myeloid leukemia | Ohio State University | Kiadis Pharma Netherlands BV | Payment unspecified | 2/26/20 |
Orgenesis to provide point-of-care platform for John Hopkins University to develop and supply cell and gene based clinical therapeutics | Orgenesis Inc. | Johns Hopkins University | Payment unspecified | 2/19/20 |
Toa Eiyo to develop Osaka University's CNT-01 against triglyceride deposit cardiomyovasculopathy worldwide | Osaka University | Toa Eiyo KK | Payment unspecified | 2/17/20 |
Peking University and Sino Biological to develop BD-368-2 for COVID-19 | Peking University | Sino Biological Inc. | Payment unspecified | 2/9/20 |
Perelman School to advance the development of Active Biotech's tasquinimod for multiple myeloma | Perelman School of Medicine | Active Biotech AB | Payment unspecified | 2/5/20 |
PCOM and Organic Remedies to study medical marijuana for therapeutic applications, including chronic pain and opioid management | Philadelphia College of Osteopathic Medicine | Organic Remedies | Payment unspecified | 2/24/20 |
Gibson Oncology to commercialize Purdue University's azaindenoisoquinolines against cancer worldwide | Purdue University | Gibson Oncology LLC | Payment unspecified | 2/10/20 |
RFU and Exicure to develop therapeutics for genetic diseases | Rosalind Franklin University of Medicine & Science | Exicure Inc. | Payment unspecified | 2/13/20 |
BARDA and Sanofi to develop coronavirus vaccine candidate using recombinant DNA platform for Coronavirus infection | Sanofi Pasteur Inc. | U.S. Department of Health and Human Services | Payment unspecified | 2/18/20 |
Enochian Biosciences acquires hepatitis B virus therapy from Seraph Research Institute | Seraph Research Institute | Enochian Biosciences Inc. | Payment unspecified | 2/2/20 |
Shanghai Ruijin to conduct clinical study of Cellular Biomedicine's mesenchymal stem cell exosomes for novel coronavirus pneumonia | Shanghai Ruijin Hospital | Cellular Biomedicine Group Inc. | Payment unspecified | 2/28/20 |
TMU and Meridigen Biotech to develop UMC119-06 for acute respiratory distress syndrome | Shuang Ho Hospital | Meridigen Biotech Co. Ltd. | Payment unspecified | 2/3/20 |
SERI and Gemini to identify targets using precision medicine GEM-103 for dry age-related macular degeneration and other ocular disorders | Singapore Eye Research Institute | Gemini Therapeutics | Payment unspecified | 2/26/20 |
Southern Research to test Tonix's TNX-1800 for COVID-19 infection | Southern Research Institute | Tonix Pharmaceuticals Inc. | Payment unspecified | 2/26/20 |
Spaulding Clinical Research to conduct clinical trials for FDA's drugs for prolongation of QT | Spaulding Clinical | Food and Drug Administration | $5.00 | 2/27/20 |
Cystic Fibrosis Foundation to support the development of Synspira Therapeutics' SNSP-003 to treat malabsorption syndromes | Synspira Therapeutics Inc. | Cystic Fibrosis Foundation | Payment unspecified | 2/12/20 |
Beroni and Tianjin University to develop nanobodies for the COVID-19 infection | Tianjin University | Beroni Group Ltd. | Payment unspecified | 2/20/20 |
TMDU and ACT Genomics to evaluate genomic profiles in Japanese cancer patients | Tokyo Medical and Dental University | ACT Genomics Co. Ltd. | Payment unspecified | 2/12/20 |
Tsinghua University and Liaoning Cheng Da to develop polypeptide COVID-19 vaccine | Tsinghua University | Liaoning Cheng Da Co. Ltd. | Payment unspecified | 2/11/20 |
NIH and Tuskegee University to develop immunotherapy approaches for cancers and other diseases | Tuskegee University | National Institutes of Health | Payment unspecified | 2/27/20 |
Sanofi Pasteur and HHS to advance COVID-19 vaccine | U.S. Department of Health and Human Services | Sanofi Pasteur Inc. | Payment unspecified | 2/18/20 |
University of Campinas and Entourage to identify and develop therapeutic candidates from 240 cannabis varieties for refractory epilepsy | Universidade Estadual de Campina | Entourage Phytolab | Payment unspecified | 2/3/20 |
University of Alaska Fairbanks to grant rights of drug composition patent to Be Cool Pharmaceutics for inducing hibernation state | University of Alaska Fairbanks | Be Cool Pharmaceutics LLC | Payment unspecified | 2/3/20 |
University of Arkansas and NIBEC to conduct research and develop peptide drugs against blood cancer treatments | University of Arkansas for Medical Sciences | Nano Intelligent Biomedical Engineering Corporation Co. Ltd. | Payment unspecified | 2/11/20 |
UCI and Agex to develop and commercialize cell therapies using Purestem technology for neurological disorders | University of California Irvine | Agex Therapeutics Inc. | Payment unspecified | 2/3/20 |
Benevolentai and University of California to discover and develop non-invasive therapeutic treatments for cerebral cavernous malformations | University of California San Diego | Benevolentai Ltd. | Payment unspecified | 2/12/20 |
Genprex to use University of Pittsburgh's gene therapy candidate for the treatment of type 1 and type 2 diabetes | University of Pittsburgh | Genprex Inc. | Payment unspecified | 2/11/20 |
GSK and University of Queensland to develop 2019-nCoV vaccine using pandemic vaccine adjuvant platform technology | University of Queensland | Glaxosmithkline plc | Payment unspecified | 2/3/20 |
CSL and University of Queensland to develop COVID-19 vaccine using MF59 adjuvant platform technology | University of Queensland | CSL Ltd. | Payment unspecified | 2/12/20 |
NCI to enter a CRADA with VBL Therapeutics to evaluate VB-111 in combination in phase II study with nivolumab in patients with metastatic colorectal cancer | VBL Therapeutics | National Cancer Institute | Payment unspecified | 2/20/20 |
WPD Pharmaceuticals to use Wake Forest University's intellectual property rights related to WPD-101, WPD-102 and WPD-103 for glioblastoma and other tumors | Wake Forest University | WPD Pharmaceuticals Inc. | Payment unspecified | 2/24/20 |
Dianomi Therapeutics licensed a second suite of intellectual property from the Wisconsin Alumni Research Foundation to expand use of mineral-coated microparticle technology into nucleic acid therapy | Wisconsin Alumni Research Foundation | Dianomi Therapeutics Inc. | Payment unspecified | 2/11/20 |
Brigham & Women to evaluate perioperative use of Acelrx's Dsuvia for spine surgery | Acelrx Pharmaceuticals Inc. | Brigham & Women's Hospital | Payment unspecified | 3/6/20 |
UAB to develop Altimmune's AdCOVID against COVID-19 | Altimmune Inc. | University of Alabama at Birmingham | Payment unspecified | 3/30/20 |
Allovir expanded the research and development collaboration with Baylor College of Medicine to use Allovir's technology for the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies including, ALVR-106 to combat SARS-CoV-2 | Baylor College of Medicine | Allovir Inc. | Payment unspecified | 3/23/20 |
Kuur Therapeutics and Baylor College of Medicine to develop cancer therapies using a CAR NK T-cell therapy platform | Baylor College of Medicine | Kuur Therapeutics Inc. | Payment unspecified | 3/10/20 |
Berkeley to form consortium with VUMC for discovery of neutralizing antibodies against COVID-19 and other viruses | Berkeley Lights Inc. | Vanderbilt University Medical Center, US | Payment unspecified | 3/25/20 |
Janssen Pharmaceutical and Beth Israel Deaconess Medical Center to develop a vaccine to treat COVID-19 infection | Beth Israel Deaconess Medical Center | Janssen Pharmaceuticals Inc. | Payment unspecified | 3/13/20 |
CCFV and IMV to conduct preclinical and clinical studies of DPX-COVID-19 for Coronavirus infection | Canadian Center for Vaccinology | IMV Inc. | Payment unspecified | 3/18/20 |
Ideaya Biosciences expanded research collaboration with Cancer Research UK and the University of Manchester to develop small-molecule inhibitors of poly(ADP-ribose) glycohydrolase (PARG) | Cancer Research UK and the University of Manchester | Ideaya Biosciences Inc. | Payment unspecified | 3/11/20 |
Celldex Therapeutics to receive a $1.7M payment related to a 2013 agreement with Rockefeller University to perform manufacturing and development services for broadly neutralizing antibodies against HIV, including clinical-stage candidates 3-BNC-117 and 10-1074 | Celldex Therapeutics Inc. | Rockefeller University | $1.70 | 3/3/20 |
Avectas and CCRM to accelerate nonviral cell engineering platform to develop therapies for immune-oncology and gene editing | Centre for Commercialization of Regenerative Medicine | Avectas Ltd. | Payment unspecified | 3/3/20 |
Pluristem and Charite University to develop PLX cell product candidates for COVID-19 | Charite Universitaetsmedizin Berlin | Pluristem Therapeutics Inc. | Payment unspecified | 3/12/20 |
RDIF and GC Khimrar to form a joint venture to develop and manufacture Favipiravir and antiviral drugs against coronavirus infection in Russia | Chemrar High Tech Center | Russian Direct Investment Fund | Payment unspecified | 3/26/20 |
Sihuan Pharmaceutical and Ministry of Science and Technology to conduct clinical research on Favipiravir tablet against COVID-19 | Chinese Ministry of Science and Technology | Sihuan Pharmaceutical Holdings Group Ltd. | Payment unspecified | 3/2/20 |
GARDP to use Daiichi's chemical library to identify the antibacterial compounds for drug resistant infections | Daiichi Sankyo Co. Ltd. | Global Antibiotic Research and Development Partnership | Payment unspecified | 3/12/20 |
Absolute Antibody and Technical University of Denmark to develop engineered recombinant antibodies specific for animal toxins, such as from snake venoms | Denmark Technical University | Absolute Antibody | Payment unspecified | 3/20/20 |
Ridgeback Biotherapeutics to develop Drug Innovations at Emory's EIDD-2801 against COVID-19 treatment | Drug Innovations at Emory LLC | Ridgeback Biotherapeutics LP | Payment unspecified | 3/19/20 |
Diverse Biotech and Duke University Medical Center to evaluate the efficacy of cannabidiol compounds in glioblastoma animal models | Duke University Medical Center | Diverse Biotech Inc. | Payment unspecified | 3/30/20 |
Duke-NUS Medical School and Arcturus Therapeutics to develop Coronavirus vaccine using STARR technology | Duke-NUS Medical School | Arcturus Therapeutics Inc. | Payment unspecified | 3/4/20 |
Wuxi Biologics to evaluate Dyadic's C1 gene expression platform for vaccine and drug development and manufacturing | Dyadic International Inc. | Wuxi Biologics | Payment unspecified | 3/30/20 |
Anabios and FDA to study adult human primary cardiomyocytes as standards for reference of gene expression and localization of functional proteins | Food and Drug Adminstration | Anabios Corp. | Payment unspecified | 3/10/20 |
Fred Hutchinson to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer | Fred Hutchinson Cancer Research Center | Lonza Group AG | Payment unspecified | 3/9/20 |
Ziphius Therapeutics to use Ghent University's mRNA platform to develop ZIP-1642 for COVID-19 | Ghent University | Ziphius Therapeutics NV | Payment unspecified | 3/23/20 |
Astellas Pharma and Gifu University to develop bacterial infection treatments using engineered bacteriophages | Gifu University | Astellas Pharma Inc. | Payment unspecified | 3/18/20 |
Grifols and BARDA to develop first plasma derived hyperimmune globulin treatment for COVID-19 | Grifols SA | U.S. Biomedical Advanced Research and Development Authority | Payment unspecified | 3/25/20 |
Demelle to use Moffitt Cancer Center's technology to develop DM-3001 against pancreatic cancer worldwide | H Lee Moffitt Cancer Center and Research Institute | Demelle Oncopharma LLC | Payment unspecified | 3/4/20 |
Themis to conduct research and identify a coronavirus vaccine using Institut Pasteur's vaccine technology | Institut Pasteur | Themis Bioscience GmbH | Payment unspecified | 3/20/20 |
ISB and Isoplexis to collaborate to study COVID-19 using single cell functional proteomics platform | Institute For Systems Biology | Isoplexis Corp. | Payment unspecified | 3/24/20 |
Institute of Materia Medica and Cyclica to discover and design multi-targeted antiviral drug candidates using Matchmaker technology for COVID-19 | Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College | Cyclica Inc. | Payment unspecified | 3/5/20 |
Junshi Biosciences and IMCAS to jointly develop neutralizing antibodies for the treatment of COVID-19 | Institute of Microbiology, CAS | Shanghai Junshi Biosciences Co. Ltd. | Payment unspecified | 3/20/20 |
Butantan Institute and Boston Children's Hospital to develop vaccine against pneumonia | Instituto Butantan | Boston Children's Hospital | Payment unspecified | 3/31/20 |
Batavia to manufacture IAVI's replication-competant VSV for the treatment of COVID-19 infection, Marburg and Ebola virus infection | International AIDS Vaccine Initiative | Batavia Biosciences BV | Payment unspecified | 3/5/20 |
Kaiser to conduct phase I clinical trial for Moderna's mRNA-1273 against COVID-19 | Kaiser Permanente Washington Health Research Institute | Moderna Inc. | Payment unspecified | 3/16/20 |
Zelluna and Karolinska Institute to develop and commercialize T-cell receptor natural killer products for the treatment of patients with solid cancers | Karolinska Institute | Zelluna Immunotherapy A/S | Payment unspecified | 3/12/20 |
Lift Biosciences and King’s College London to develop an induced pluripotent stem cells version of its N1a neutrophil cancer cell therapy product, N-LIfT | King’s College London | Lift Biosciences Ltd. | Payment unspecified | 3/26/20 |
SK Chemicals and KCDC to develop synthetic antigen-based subunit vaccine for COVID-19 | Korea Center for Disease Control & Prevention | SK Chemicals Co. Ltd. | Payment unspecified | 3/18/20 |
Horama to use LUMC's patent and know-how to develop HORA-001 for pathogenic CRB1 gene mutations associated inherited retinal dystrophy worldwide | Leiden University Medical Center | Horama SA | Payment unspecified | 3/18/20 |
Kiromic Biopharma to use Longwood University’s patent rights related to PD-1-AR against solid tumor worldwide | Longwood University | Kiromic Biopharma Inc. | $0.01 | 3/25/20 |
Royalty Pharma acquires Massachusetts General Hospital's royalty interest in Entyvio for ulcerative colitis, Crohn's disease and inflammatory bowel disease | Massachusetts General Hospital | Royalty Pharma | $94.00 | 3/5/20 |
Medicines Patent to commercialize Medincell's ivermectin against malaria in low- and middle-income countries | Medincell SA | Medicines Patent Pool | Payment unspecified | 3/25/20 |
Mount Sinai and Harbour Biomed to develop biotherapies using H2L2 Harbour Mice platform for cancer and COVID-19 | Mount Sinai Health System | Harbour Biomed Therapeutics Ltd. | Payment unspecified | 3/6/20 |
Gene Techno Science and Nagoya University to develop a therapy against spinal cord injury | Nagoya University | Gene Techno Science Co. Ltd. | Payment unspecified | 3/5/20 |
National Cancer Institute to study safe nanotechnology-based cancer therapeutics using Curadigm's Nanoprimer technology | National Cancer Institute | Curadigm | Payment unspecified | 3/9/20 |
Adimmune and Taiwanese National Health Research Institutes to develop Covid-19 vaccine | National Health Research Institutes | Adimmune Corp. | Payment unspecified | 3/2/20 |
Vir Biotechnology and National Institute of Allergy and Infectious Diseases to research on monoclonal antibodies for coronaviruses, including SARS, MERS and SARS-CoV-2 | National Institute of Allergy and Infectious Diseases | Vir Biotechnology Inc. | Payment unspecified | 3/11/20 |
National Institute of Allergy and Infectious Diseases to evaluate Airway's AT-100 for coronavirus | National Institute of Allergy and Infectious Diseases | Airway Therapeutics LLC | Payment unspecified | 3/11/20 |
NIAID to conduct trial for Green Cross Labcell’s natural killer-cell combination therapy against COVID-19 | National Institute of Allergy and Infectious Diseases | Green Cross Labcell | Payment unspecified | 3/30/20 |
NIID to evaluate AIM Immunotech's Ampligen for the treatment of COVID-19 infection | National Institute of Infectious Diseases Japan | AIM Immunotech Inc. | Payment unspecified | 3/9/20 |
VBI Vaccines and NRC of Canada to develop a pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS | National Research Council of Canada | VBI Vaccines Inc. | Payment unspecified | 3/31/20 |
NRC and Edesa Biotech to develop immunotherapies and identify the lead candidate for vitiligo and other diseases worldwide | National Research Council of Canada | Edesa Biotech Inc. | Payment unspecified | 3/12/20 |
Bellus Health to acquire BLU-5937 and P2X3 antagonists IP assets from admare Bioinnovations' Neomed Institute | Neomed Institute | Bellus Health Inc. | Payment unspecified | 3/23/20 |
Netherlands Cancer Institute and Revolution Medicines to conduct phase I/Ib trial on combination of RMC-4630 with an ERK Inhibitor for tumors harboring RAS mutations | Netherlands Cancer Institute | Revolution Medicines Inc. | Payment unspecified | 3/9/20 |
Gene Techno and Oita University to develop therapy for peripheral nerve paralysis | Oita University | Gene Techno Science Co. Ltd. | Payment unspecified | 3/5/20 |
Ology Bioservices to develop, manufacture and deliver monoclonal antibody for Department of Defense to treat COVID-19 virus | Ology Bioservices Inc. | U.S. Department of Defense | $14.00 | 3/23/20 |
Osaka University and Anges to develop DNA vaccine for Coronavirus infection using DNA plasmid technology | Osaka University | Anges MG Inc. | Payment unspecified | 3/5/20 |
Eusa Pharma and Papa Giovanni XXIII Hospital to conduct research study on siltuximab for COVID-19 | Ospedale Papa Giovanni XXIII | Eusa Pharma | Payment unspecified | 3/18/20 |
The Rising Tide Foundation and Oxford University Innovation to develop MMD drugs against cancer | Oxford University Innovation | Rising Tide Foundation | $0.30 | 3/5/20 |
Parker Institute to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer | Parker Institute for Cancer Immunotherapy | Lonza Group AG | Payment unspecified | 3/9/20 |
Rega Institute to conduct antiviral screening on Johnson & Johnson's compound libraries including vaccine against COVID-19 | Rega Institute for Medical Research | Johnson & Johnson | Payment unspecified | 3/30/20 |
Bridge Medicines and The Rockefeller University to develop ENL-YEATS inhibitors against acute leukemia | Rockefeller University | Bridge Medicines LLC | Payment unspecified | 3/16/20 |
Sabin Vaccine to manufacture Ebola Sudan and Marburg vaccines for VRC | Sabin Vaccine Institute | National Institute of Allergy and Infectious Diseases | $5.30 | 3/5/20 |
Exscientia and Scripps Research Institute to screen and identify antiviral drugs against COVID-19 | Scripps Research Institute | Exscientia Ltd. | Payment unspecified | 3/31/20 |
Haihe Biopharma to develop Shanghai Institute of Materia's HH-2853 for non-Hodgkin's lymphoma and advanced solid tumors in the U.S. | Shanghai Institute of Materia Medica of the Chinese Academy of Sciences | Haihe Biopharma | Payment unspecified | 3/17/20 |
Haihe Biopharma to develop Shanghai Institute of Materia Medica of the Chinese Academy of Sciences' SOMCL-18-202 against cancer worldwide | Shanghai Institute of Materia Medica of the Chinese Academy of Sciences | Haihe Biopharma | Payment unspecified | 3/18/20 |
Stanford University to evaluate Lonza's Cocoon platform for manufacturing of cell therapies against cancer | Stanford University School of Medicine | Lonza Group AG | Payment unspecified | 3/9/20 |
Sunnybrook Health Sciences Centre and Apotex to conduct a phase II clinical stidy for Kaletra in COVID-19 patients | Sunnybrook Health Sciences Centre | Apotex Inc. | Payment unspecified | 3/18/20 |
Temple University to evaluate anti-viral activity of Can-Fite's piclidenoson on coronaviruses viral load in a mammalian cell model system | Temple University | Can-Fite Biopharma Ltd. | Payment unspecified | 3/13/20 |
LLS to conduct phase I/IIb clinical study of Tolero's dubermatinib for acute myeloid leukemia | The Leukemia & Lymphoma Society | Tolero Pharmaceuticals Inc. | Payment unspecified | 3/26/20 |
Tsinghua University and Brii Biosciences to discover, develop, manufacture and commercialize fully human neutralizing monoclonal antibodies for COVID-19 | Tsinghua University | Brii Biosciences Ltd. | Payment unspecified | 3/31/20 |
VUMC to identify antibodies using Twist Bioscience's antibody drug discovery libraries and synthetic genes for COVID-19 | Twist Bioscience Corp. | Vanderbilt University Medical Center | Payment unspecified | 3/26/20 |
Innovation to enter material transfer agreement with an undisclosed U.S. university to evaluate brilacidin against COVID-19 | Undisclosed U.S. university | Innovation Pharmaceuticals Inc. | Payment unspecified | 3/6/20 |
University hospital Ghen to evaluate Partner Therapeutics' Leukine for the treatment of respiratory illness associated with COVID-19 | Universitair Ziekenhuis Gent | Partner Therapeutics Inc. | Payment unspecified | 3/24/20 |
University of Alberta to conduct a phase I trial for Protokinetix's PKX-001 against type I diabetes | University of Alberta | Protokinetix Inc. | Payment unspecified | 3/24/20 |
Cerus and University of California to optimize convalescent plasma therapy for COVID-19 | University of California | Cerus Corp. | Payment unspecified | 3/26/20 |
Epivax and University of Georgia to develop a coronavirus SARS-CoV-2 vaccine and immunology | University of Georgia | Epivax Inc. | Payment unspecified | 3/4/20 |
CEL-SCI and University of Georgia to develop ligand epitope antigen presentation system COVID-19 immunotherapy | University of Georgia | CEL-SCI Corp. | Payment unspecified | 3/23/20 |
Spherix to use University of Maryland's patents related to methods of treating coronavirus infection | University of Maryland Batimore | Spherix Inc. | Payment unspecified | 3/6/20 |
University of Miami and Heat Biologics to develop a vaccine targeting SARS-CoV-2 coronavirus infection | University of Miami | Heat Biologics Inc. | Payment unspecified | 3/5/20 |
Rising Pharma and University of Minnesota to conduct clinical trial exploring hydroxychloroquine for COVID-19 | University of Minnesota | Rising Pharma Holdings Inc | Payment unspecified | 3/27/20 |
Askbio and UNC to develop and commercialize gene therapy to correct deficiency in UBE3A gene for Angelman syndrome | University of North Carolina | Asklepios Biopharmaceutical Inc. | Payment unspecified | 3/18/20 |
OUHSC and Pure MHC to develop vaccine for COVID-19 | University of Oklahoma Health Sciences Center | Puremhc LLC | Payment unspecified | 3/20/20 |
University of Pittsburgh to support Southwest Research Institute on the synthesis and compound design | University of Pittsburgh | Southwest Research Institute | Payment unspecified | 3/24/20 |
Dynavax and University of Queensland as part of a coalition for epidemic preparedness initiative to develop COVID-19 vaccine | University of Queensland | Dynavax Technologies Corp. | Payment unspecified | 3/2/20 |
University of Technology Sydney to sign memorandum of understanding to use Aragen's CHO DG-44 expression system to develop therapeutic antibodies | University of Technology Sydney | Aragen Bioscience Inc. | Payment unspecified | 3/3/20 |
UTMB to conduct research on Moleculin Biotech's WP-1122 against COVID-19 infection | University of Texas Medical Branch at Galveston | Moleculin Biotech Inc. | Payment unspecified | 3/17/20 |
Q2 Solutions and UTMB to develop a novel assay for COVID-19 vaccine test | University of Texas Medical Branch at Galveston | Q Squared Solutions LLC | Payment unspecified | 3/24/20 |
UTMB to test Sorrento’s COVID-19 therapeutics in preclinical phase | University of Texas Medical Branch at Galveston | Sorrento Therapeutics Inc. | Payment unspecified | 3/31/20 |
Respirerx to use UWMRF's patents related to GABA(A) receptor allosteric neuromodulators | UWM Research Foundation Inc. | Respirerx Pharmaceuticals Inc. | Payment unspecified | 3/4/20 |
Immuron and WRAIR to test Travelan against isolates of Shigella, enterotoxigenic Escherichia coli, Vibrio cholerae and Campylobacter jejuni | Walter Reed Army Institute of Research | Immuron Ltd. | Payment unspecified | 3/11/20 |
National Health Service to award Accord Healthcare contract to supply hydroxychloroquine treatment of COVID-19 | Accord Healthcare Inc. | National Health Service | Payment unspecified | 4/27/20 |
Racemd to conduct clinical study for American Cryostem' Atcell against Duchenne muscular dystrophy patients | American Cryostem Corp. | Racemd | Payment unspecified | 4/1/20 |
ABC and BARDA to expand collection of convalescent plasma from recovered COVID-19 patients | America's Blood Centers | Biomedical Advanced Research and Development Authority | Payment unspecified | 4/27/20 |
Batavia to manufacture and distribute Wistar's rubella vaccine seed stock RA 27/3 worldwide | Batavia Biosciences BV | Wistar Institute of Anatomy & Biology | Payment unspecified | 4/29/20 |
BARDA placed a new order under the contract for the manufacturing and supply of Bavarian Nordic's Jynneos (smallpox and monkeypox vaccine, live, non-replicating), at a total value of $202 million | Bavarian Nordic A/S | U.S. Biomedical Advanced Research and Development Authority | $202.00 | 4/30/20 |
NIVDC and Beijing Biological Products Institute to develop COVID-19 vaccine | Beijing Biological Products Institute Co. Ltd. | National Institute for Viral Disease Control and Prevention of Chinese Center for Disease Control and Prevention | Payment unspecified | 4/27/20 |
Gates MRI and the Institut Pasteur to develop carbohydrate-based conjugate vaccine against Shigella flexneri and Shigella sonnei | Bill & Melinda Gates Medical Research Institute | Institut Pasteur | Payment unspecified | 4/16/20 |
Biobridge and Xbiotech to develop COVID-19 treatment worldwide | Biobridge Global | Xbiotech Inc. | Payment unspecified | 4/3/20 |
BMT CTN to conduct phase I/II study on Kiadis' KNK-002 against blood cancer | Blood and Marrow Transplant Clinical Trials Network | Kiadis Pharma Netherlands BV | Payment unspecified | 4/9/20 |
Brigham and Women's Hospital to evaluate safety and efficacy of Fujifilm's Avigan tablet for COVID-19 infection in the U.S. | Brigham & Women's Hospital | Fujifilm Holdings Corp. | Payment unspecified | 4/9/20 |
Brown University and Applied Biology to launch drug discovery platform to identify drugs against COVID-19 | Brown University | Applied Biology Inc. | Payment unspecified | 4/6/20 |
Central China Normal University and East China University of Science & Technology to develop FBPase inhibitors for type 2 diabetes | Central China Normal University | East China University of Science & Technology | Payment unspecified | 4/27/20 |
Healx and CTF to discover and progress artificial intelligence-derived therapies for neurofibromatosis | Children's Tumor Foundation | Healx Ltd. | Payment unspecified | 4/15/20 |
CB Therapeutics and Cleveland Clinic to manufacture psilocybin, dimethyltryptamine and 3,4-methylenedioxymethamphetamine therapeutic compounds for clinical trials to treat depression, addiction and post-traumatic stress disorder | Cleveland Clinic Foundation | CB Therapeutics Inc. | Payment unspecified | 4/20/20 |
CSHL to research on Santhera's lonodelestat for COVID-19 related-acute respiratory distress syndrome | Cold Spring Harbor Laboratory | Santhera Pharmaceuticals Holding AG | Payment unspecified | 4/27/20 |
GIS and Cyclica to develop compound design for drug discovery programs in oncology and related diseases using ligand design and ligand express platform | Cyclica Inc. | Genome Institute Of Singapore National University | Payment unspecified | 4/14/20 |
Cytiva to manufacture University of Queensland's COVID-19 vaccine | Cytiva | University of Queensland | Payment unspecified | 4/6/20 |
DWTI to develop Medrx' MRX-5LBT for postherpetic neuralgia in the U.S. | D Western Therapeutics Institute | Medrx Co. Ltd. | Payment unspecified | 4/16/20 |
Immunecyte to acquire intellectual property rights related to East China Normal University's human antibody therapeutics for COVID-19 worldwide | East China Normal University | Immunecyte Life Sciences Inc. | Payment unspecified | 4/13/20 |
SOM Biotech and Ewha Womans University to evaluate Eravacycline, Prexasertib, Cynarine for the treatment of COVID-19 | Ewha Womans University | SOM Biotech SL | Payment unspecified | 4/20/20 |
Secarna and Sun Yat-sen University to develop vaccine against COVID-19 using LNAplus technology | First Affiliated Hospital of Sun Yat-Sen University | Secarna Pharmaceuticals GmbH & Co. KG | Payment unspecified | 4/28/20 |
Pharnext and Institut Hospitalo-Universitaire Méditerranée Infection to evaluate repurposed drugs against COVID-19 virus | Fondation Mediterranee Infection | Pharnext SAS | Payment unspecified | 4/22/20 |
Van Andel Institute to conduct research on epigenetics using Foxo Bioscience's Infinium mouse DNA methylation array | Foxo Biosciences LLC | Van Andel Institute | Payment unspecified | 4/10/20 |
Moffitt to grant technology IP rights to Memgen to develop MEM-288 and additional products for cancer | H Lee Moffitt Cancer Center and Research Institute | Memgen LLC | Payment unspecified | 4/21/20 |
Hackensack University Medical Center to conduct phase II trial for Eagle’s Ryanodex in patients infected with COVID-19 | Hackensack University Medical Center | Eagle Pharmaceuticals Inc. | Payment unspecified | 4/16/20 |
Quell Therapeutics and Hannover Medical School to discover and validate of multiple CAR-Treg cell therapies against autoimmune and inflammatory diseases | Hannover Medical School | Quell Therapeutics | Payment unspecified | 4/7/20 |
Harvard Chan School and Human Vaccines Project to accelerate drug, vaccine and diagnostic development using artificial intelligence | Harvard TH Chan School of Public Health | Human Vaccines Project | Payment unspecified | 4/14/20 |
Astellas and Harvard University to initiate the drug discovery research projects and develop therapeutics against various diseases | Harvard University | Astellas Pharma Inc | Payment unspecified | 4/27/20 |
Hebrew University and Newstem to identify genes regulating pathogenicity of COVID-19 virus using embryonic stem cell platform | Hebrew University of Jerusalem | Newstem Ltd. | Payment unspecified | 4/21/20 |
Hokkaido University and Shionogi to identify drugs active against COVID-19 for zoonosis control | Hokkaido University | Shionogi and Co. Ltd. | Payment unspecified | 4/14/20 |
Hokkaido University and Shionogi to identify drugs including SARS-CoV-2 therapy active against COVID-19 | Hokkaido University | Shionogi and Co. Ltd. | Payment unspecified | 4/14/20 |
HVP to launch COVID-19 vaccine initiative with FHI 360 | Human Vaccines Project | FHI 360 | Payment unspecified | 4/23/20 |
IDRI and Ibio to develop SARS-CoV-2 virus-like particle vaccine development | Infectious Disease Research Institute | Ibio Inc. | Payment unspecified | 4/9/20 |
Institut Pasteur Korea and Union therapeutics to develop niclosamide as a treatment of COVID-19 | Institut Pasteur Korea | Union therapeutics | Payment unspecified | 4/2/20 |
Institut Pasteur Korea to develop and initiate a clinical trial of Daewoong's niclosamide against COVID-19 | Institut Pasteur Korea | Daewoong Pharmaceutical Co. Ltd. | Payment unspecified | 4/14/20 |
MSD and ISB to identify targets for the development of therapies and vaccines against coronavirus disease 19 infection | Institute for Systems Biology | Merck Sharp & Dohme (Holdings) Ltd. | Payment unspecified | 4/27/20 |
IIBR and Weizmann Institute of Science to develop therapeutics against COVID-19 | Israel Institute for Biological Research | Weizmann Institute of Science | Payment unspecified | 4/19/20 |
Gladstone Institutes and Chempartner to discover of therapeutics and diagnostics for COVID-19 | J David Gladstone Institutes | Chempartner Corp. | Payment unspecified | 4/16/20 |
Cocrystal Pharma expanded its license agreement with Kansas State University Research Foundation to include rights to additional preclinical leads and further develop certain broad-spectrum antiviral compounds for the treatment of coronavirus infections | Kansas State University Research Foundation | Cocrystal Pharma Inc. | Payment unspecified | 4/22/20 |
Epsilogen to develop KCL's MOv18 IgE against cancer | King's College London | Epsilogen Ltd. | Payment unspecified | 4/20/20 |
Mallinckrodt to support MGH’s Inomax study in severe acute respiratory distress syndrome due to COVID-19 | Massachusetts General Hospital | Mallinckrodt plc | Payment unspecified | 4/30/20 |
Max Planck Institute to evaluate Artemilife's Artemisia annua plant extract and artemisinin derivatives in laboratory cell studies against COVID-19 | Max Planck Institute of Colloids & Interfaces | Artemilife Inc. | Payment unspecified | 4/9/20 |
Provirex and Max Planck Institute to develop therapeutic approaches to clinical trials for the treatment of HIV using gene scissors | Max Planck Institute of Molecular Cell Biology and Genetics | Provirex Genome Editing Therapies GmbH | Payment unspecified | 4/30/20 |
Mayo Clinic to conduct phase II clinical trial for Viralclear Pharmaceuticals' Vicromax against COVID-19 | Mayo Clinic Foundation | Viralclear Pharmaceuticals Inc. | Payment unspecified | 4/16/20 |
Medical University of Vienna to conduct proof of concept study of Marinomed's inhalation therapy for viral pneumonia in COVID-19 | Medical University of Vienna | Marinomed Biotechnologie GmbH | Payment unspecified | 4/28/20 |
Y-mAbs to develop and commercialize antibody constructs with MSK's SADA Technology worldwide | Memorial Sloan-Kettering Cancer Center | Y-mabs Therapeutics Inc. | Payment unspecified | 4/15/20 |
CDND to purchase TPOXX courses from Meridian for the treatment of smallpox | Meridian Medical Technologies Inc. | Canadian Department of National Defence | $14.30 | 4/3/20 |
MHI and NYU Grossman to conduct COVID-19 clinical study to evaluate colchicine’s effect on complications | Montreal Heart Institute | New York University School of Medicine | Payment unspecified | 4/7/20 |
Mount Sinai and Genscript to develop antibody targeting peptide sequence of the S1 spike protein for COVID-19 | Mount Sinai Medical Center | Genscript Corp. | Payment unspecified | 4/23/20 |
Daiichi Sankyo and Nagoya Institute of Technology to develop gene therapy for retinitis pigmentosa | Nagoya Institute of Technology | Daiichi Sankyo Co. Ltd. | Payment unspecified | 4/13/20 |
T-Cure Bioscience to acquire IP rights related to TCR-based product expressing KK-LC-1 from NCI against cancer worldwide | National Cancer Institute | T-Cure Bioscience Inc. | Payment unspecified | 4/8/20 |
NCI to conduct a phase IB trial of Prolynx's PLX-038 combined with rucaparib against small-cell lung cancer | National Cancer Institute | Prolynx LLC | Payment unspecified | 4/13/20 |
Elicio Therapeutics and NCI to study ELI-002 mutant KRAS targeting mechanism in animals for mKRAS-driven cancers | National Cancer Institute | Elicio Therapeutics Inc. | Payment unspecified | 4/16/20 |
Allterum to develop National Cancer Institute's 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic leukemia | National Cancer Institute | Allterum Therapeutics Inc. | Payment unspecified | 4/21/20 |
NCBID to develop Emergex' CD8+ priming RNA virus vaccines against viral infection including SARS coronavirus infection | National Center for Biodefense and Infectious Diseases | Emergex Vaccines Ltd. | Payment unspecified | 4/22/20 |
NIAID to conduct clinical trial for Senhwa Biosciences' CX-4945 for COVID-19 | National Institute of Allergy and Infectious Diseases | Senhwa Biosciences Inc. | Payment unspecified | 4/9/20 |
NIAID to conduct to conduct clinical study for Lilly’s baricitinib for COVID-19 | National Institute of Allergy and Infectious Diseases | Eli Lilly and Co. | Payment unspecified | 4/11/20 |
NIAID to test Redhill's RHB-107 in a non-clinical studies for activity against COVID-19 | National Institute of Allergy and Infectious Diseases | Redhill Biopharma Ltd. | Payment unspecified | 4/20/20 |
NIBIOHN and Sumitomo to conduct joint research and develop DSP-0546LP against influenza | National Institute of Biomedical Innovation | Sumitomo Dainippon Pharma Co. Ltd. | Payment unspecified | 4/24/20 |
Northeastern University to grant nanomolecule technology rights to Audax for COVID-19 and other anti-viral therapy | Northeastern University | Audax Medical Inc. | Payment unspecified | 4/23/20 |
Northern Arizona University to test the antiviral activity of Oncology Venture's 2X-121 against COVID-19 infection | Northern Arizona University | Oncology Venture A/S | Payment unspecified | 4/22/20 |
Osaka University to grant intellectual property rights related to radiochemistry technology for cancer to Telix | Osaka University | Telix Pharmaceuticals Ltd. | Payment unspecified | 4/27/20 |
Paracelsus Medical University to research on Mdimune's CDV therapeutics using Biodrone | Paracelsus Medical University | Mdimune Inc. | Payment unspecified | 4/30/20 |
Peking University to grant DCP-118 rights to Yantai Dongcheng against thrombosis worldwide | Peking University | Yantai Dongcheng Biochemicals Co. Ltd. | $26.70 | 4/21/20 |
Bayer and PHRI to identify and evaluate COVID-19 treatments including chloroquine and interferon beta-1b | Population Health Research Institute | Bayer AG | $1.08 | 4/21/20 |
NHGRI to fund Primordial to develop enzymes for DNA synthesis with deep learning and combinatorial genetics | Primordial Genetics Inc. | National Human Genome Research Institute | $0.37 | 4/9/20 |
PCCTC to support the phase II clinical trial expansion of Cellcentric's CCS-1477 against cancer in the U.S. | Prostate Cancer Clinical Trials Consortium | Cellcentric Ltd. | Payment unspecified | 4/7/20 |
Providence Cancer Institute to conduct phase I clinical trial of Oncosec's CORVax-12 to treat COVID-19 | Providence Cancer Institute at Providence Hospital | Oncosec Medical Inc. | Payment unspecified | 4/6/20 |
Epimab and QIMR Berghofer to evaluate bispecific target combinations using Fabs-In-Tandem Immunoglobulin against cancer | QIMR Berghofer Medical Research Institute | Epimab Biotherapeutics Inc. | Payment unspecified | 4/23/20 |
UCB and QMUL to develop antibodies against Imood protein in mental disorders | Queen Mary University of London | UCB SA | Payment unspecified | 4/21/20 |
Queen's University to conduct a phase IIa clinical trial for Orbsen's Orbcel against COVID-19 | Queen's University | Orbsen Therapeutics Ltd. | Payment unspecified | 4/8/20 |
Fusion Antibodies and Queen's University Belfast to develop new therapeutic molecules against COVID-19 disease | Queens University of Belfast | Fusion Antibodies plc | Payment unspecified | 4/15/20 |
Innocan and Ramot to develop cell therapy product using cannabidiol-loaded exosomes for the treatment of COVID-19 infection | Ramot at Tel Aviv University | Innocan Pharma Corp. | $0.45 | 4/17/20 |
Sarepta and USAMRIID to sign CRADA to identify antisense oligonucleotides using phosphorodiamidate morpholino oligomer platform for COVID-19 | Sarepta Therapeutics Inc. | U.S. Army Medical Research Institute of Infectious Diseases | Payment unspecified | 4/28/20 |
Blue Water Vaccines to develop St. Jude Children's Research Hospital's Streptococcus pneumoniae vaccine | St. Jude Children's Research Hospital | Blue Water Vaccines Inc. | Payment unspecified | 4/10/20 |
NCI to enter into CARDA with T-Cure Bioscience to support the preclinical and clinical research to develop the TCR product against cancer | T-Cure Bioscience Inc. | National Cancer Institute | Payment unspecified | 4/8/20 |
TFF enters into CRADA with USAMRIID to study TFF technology to produce monoclonal antibody, vaccines against biodefense threats | TFF Pharmaceuticals Inc. | US Army Medical Research Institute of Infectious Diseases | Payment unspecified | 4/15/20 |
Oxford Biomedica and Jenner Institute to develop ChAdOx1 nCov-19 for COVID-19 infection | The Jenner Institute | Oxford Biomedica plc | Payment unspecified | 4/8/20 |
Chemrar and NMRCPN to develop drugs for mental disorders and conduct clinical trial on CD-008-0045 for anxiety and depressive disorders | The St.Petersburg V.M.Bekhterev Psychoneurological Research Institute | Chemrar High Tech Center | Payment unspecified | 4/20/20 |
Karolinska Development and Liverpool University to conduct a preclinical research to study the inhibitory effect of tafoxiparin against COVID-19 | The University of Liverpool | Karolinska Development AB | Payment unspecified | 4/17/20 |
Thomas Jefferson to conduct phase II study of intranasal vazegepant for the treatment of COVID-19 infection associated pulmonary complications | Thomas Jefferson University | Biohaven Pharmaceutical Holding Co. Ltd. | Payment unspecified | 4/9/20 |
Chiles Research to use Trialtus's CL7/Im7 system to monitor antibody responses to SARS-CoV-2 in patients dosed with a COVID-19 infection vaccine | Trialtus Bioscience LLC | Providence Cancer Center, Earle A. Chiles Research Institute | Payment unspecified | 4/16/20 |
Trilink to manufacture self-amplifying RNA for Imperial's COVID-19 vaccine development | Trilink Biotechnologies | Imperial College London | Payment unspecified | 4/27/20 |
University of Copenhagen to grant patent rights of uPAR-targeting molecules to Fluoguide | University College Copenhagen | Fluoguide A/S | Payment unspecified | 4/23/20 |
Mind Medicine to use University Hospital Basel's LSD and other psychedelic compound related patents worldwide | University Hospital Basel | Mind Medicine Inc. | Payment unspecified | 4/1/20 |
University Hospitals to conduct clinical trial for Arms Pharmaceutical's ARMS-I against COVID-19 infection | University Hospitals of Cleveland | Arms Pharmaceutical LLC | Payment unspecified | 4/2/20 |
University of California and Verndari to develop COVID-19 vaccine using Vaxipatch, dermal patch technology | University of California Davis | Verndari Inc. | Payment unspecified | 4/29/20 |
University of Dundee and Amphista Therapeutics to develop bifunctional small molecule therapy against cancer | University of Dundee | Amphista Therapeutics Ltd. | Payment unspecified | 4/7/20 |
University of Edinburgh and Cyclacel Pharmaceutical to evaluate fadraciclib and seliciclib in patients with COVID-19 disease | University of Edinburgh | Cyclacel Pharmaceuticals Inc. | Payment unspecified | 4/20/20 |
University of Georgia to conduct COVID-19 glycan analysis using MOBILion Systems' SLIM separations technology | University of Georgia | Mobilion Systems Inc. | Payment unspecified | 4/21/20 |
University of Georgia to evaluate TFF's thin film freezing technology used in dry powder universal influenza vaccine for influenza infections | University of Georgia | TFF Pharmaceuticals Inc. | Payment unspecified | 4/9/20 |
University of Illinois and Vanda Pharma for investigation of small molecules to treat COVID-19 | University of Illinois | Vanda Pharmaceuticals Inc. | Payment unspecified | 4/8/20 |
University of Iowa and University of Georgia to develop MERS vaccine for COVID-19 infection | University of Iowa | University of Georgia | Payment unspecified | 4/6/20 |
University of Lausanne Hospitals to develop Prokarium's Salmonella Typhi Ty21a for the treatment of non-muscle invasive bladder cancer worldwide | University of Lausanne Hospitals | Prokarium | Payment unspecified | 4/28/20 |
AIkido Pharma to develop University of Maryland Baltimore's antiviral compounds against Influenza virus, SARS-CoV, MERS-CoV, Ebola virus and Marburg virus | University of Maryland Baltimore County | AIkido Pharma Inc. | Payment unspecified | 4/21/20 |
Scancell and University of Nottingham to develop SARS-CoV-2 vaccine for COVID-19 infection | University of Nottingham | Scancell Ltd. | Payment unspecified | 4/23/20 |
University of Ottawa to study Bold Therapeutics' BOLD-100 in the treatment of COVID-19 | University of Ottawa | Bold Therapeutics Inc. | Payment unspecified | 4/15/20 |
University of Oxford to conduct clinical study of Accord's hydroxychloroquine for the prevention of COVID-19 infection | University of Oxford | Accord Healthcare Inc. | Payment unspecified | 4/1/20 |
Astrazeneca to develop and distribute University of Oxford's ChAdOx1 nCoV-19 against COVID-19 worldwide | University of Oxford | Astrazeneca plc | Payment unspecified | 4/30/20 |
University of Queensland and Viroclinics to conduct preclinical studies on COVID-19 project | University of Queensland | Viroclinics Biosciences | Payment unspecified | 4/9/20 |
Eurofarma and ICB-USP to repurpose existing drugs against COVID-19 | University of Sao Paulo | Eurofarma | Payment unspecified | 4/23/20 |
UTMB to test Flow Pharma’s Flowvax COVID-19 vaccine | University of Texas Medical Branch at Galveston | Flow Pharma Inc. | Payment unspecified | 4/8/20 |
Taysha and UT Southwestern to translate AAV gene therapies for monogenic central nervous system diseases | University of Texas Southwestern Medical Center | Taysha Gene Therapies | Payment unspecified | 4/29/20 |
University of Valencia to grant patent rights of Christensenella’s applications to LNC for mood disorders worldwide | University of Valencia | LNC Therapeutics SA | Payment unspecified | 4/15/20 |
University of Virginia to evaluate Diffusion Pharmaceuticals' trans sodium crocetinate against acute respiratory distress syndrome in COVID-19 patients | University of Virginia | Diffusion Pharmaceuticals LLC | Payment unspecified | 4/1/20 |
University of Wisconsin–Madison to initiate the development of Flugen's Coroflu vaccine against COVID-19 | University of Wisconsin-Madison | Flugen Inc. | Payment unspecified | 4/2/20 |
University of Wisconsin and Revive to evaluate formulations and drug delivery technology based psilocybin pharmaceuticals | University of Wisconsin-Madison | Revive Therapeutics Ltd. | Payment unspecified | 4/21/20 |
Halovax and VIC to develop a vaccine against COVID-19 infection using self-assembling vaccine technology | Vaccine and Immunotherapy Center | Halovax | Payment unspecified | 4/2/20 |
VUMC and Astrazeneca to identify antibody treatment for COVID-19 | Vanderbilt University Medical Center | Astrazeneca plc | Payment unspecified | 4/8/20 |
Vanderbilt Vaccine Center to use Pacific Biosciences' sequencing technology to study the human B-cell response to the virus, to identify therapeutics or protective antibodies | Vanderbilt Vaccine Center | Pacific Biosciences of California Inc. | Payment unspecified | 4/8/20 |
Flinders University to use Vaxine's Oracle cloud technology and vaccine technology to conduct test and develop a vaccine candidate against the SARS-CoV-2 coronavirus | Vaxine Pty Ltd. | Flinders University of South Australia | Payment unspecified | 4/3/20 |
Venatorx Pharmaceuticals and GARDP to develop and commercialize cefepime-taniborbactam against urinary tract infection, multidrug-resistant infections and bacterial infections worldwide | Venatorx Pharmaceuticals Inc. | Global Antibiotic Research and Development Partnership | Payment unspecified | 4/29/20 |
Vanda Pharmaceuticals and UW Medicine to perform pharmacogenetics study in patients with COVID-19 Infection | Washington University School of Medicine | Vanda Pharmaceuticals Inc. | Payment unspecified | 4/15/20 |
Yale and Veracyte to advance the first genomic test for identifying disease progression in idiopathic pulmonary fibrosis patients | Yale University | Veracyte Inc. | Payment unspecified | 4/23/20 |
Yale University to conduct a clinical trial of Medicinova's MN-166 against acute respiratory distress syndrome in COVID-19 | Yale University | Medicinova Inc. | Payment unspecified | 4/27/20 |
Symphogen and University of Aarhus to develop antibody therapies for COVID-19 | Aarhus University | Symphogen A/S | Payment unspecified | 5/12/20 |
Avexis to manufacture Massachusetts General Hospital's AAVCOVID vaccine for COVID-19 | Avexis Inc. | Massachusetts General Hospital | Payment unspecified | 5/29/20 |
Mymetics and Baylor College of Medicine to develop COVID-19 vaccines | Baylor College of Medicine | Mymetics Corp. | Payment unspecified | 5/18/20 |
Milliporesigma and Baylor College of Medicine to extend ongoing collaboration to advance a manufacturing platform to fight COVID-19 | Baylor College of Medicine | Milliporesigma | Payment unspecified | 5/27/20 |
Brown University to evaluate Restorbio's RTB-101 for the treatment of COVID-19 infection in nursing home residents | Brown University School of Public Health | Restorbio Inc. | Payment unspecified | 5/28/20 |
Canadian Immunization Research Network to conduct future clinical trails of CanSino Biologics' Ad5-nCoV against COVID-19 in Canada | Canadian Immunization Research Network | Cansino Biologics Inc. | Payment unspecified | 5/12/20 |
Cancer Research UK to conduct phase I trial for Crescendo’s CB-213 in patients with solid tumours | Cancer Research UK | Crescendo Biologics Ltd. | Payment unspecified | 5/5/20 |
Cancer Research and Latus to study repurposed camostat in SPIKE-1 trial for COVID-19 | Cancer Research UK | Latus Therapeutics | Payment unspecified | 5/29/20 |
UCL to receive rights to manufacture Cerveau's imaging agent 18FMK-6240 for Neurodegenerative diseases including Alzheimer's disease | Cerveau Technologies Inc. | University College London | Payment unspecified | 5/4/20 |
NIBEC and Chungbuk to sign MOU to jointly research on development of peptide for treatment of viral infections and inflammation | Chungbuk National University | Nano Intelligent Biomedical Engineering Co. Ltd. | Payment unspecified | 5/29/20 |
Regeneron and CCPM to produce genomic data of DNA samples to aid in drug discovery, genomic and precision medicine | Colorado Center for Personalized Medicine (CCPM) | Regeneron Genetics Center LLC | Payment unspecified | 5/11/20 |
Oncogenuity and Columbia University to develop oligonucleotides for cancers and COVID-19 worldwide | Columbia University | Oncogenuity Inc. | Payment unspecified | 5/8/20 |
Columbia University and Atomwise to discover drug candidates targeting Nucleocapsid for COVID-19 and other coronaviruses | Columbia University | Atomwise | Payment Unspecified | 5/21/20 |
CoVIg-19 Plasma Alliance and NIAID to test the safety, tolerability and efficacy of the hyperimmune therapy in COVID-19 patiens | CoVIg-19 Plasma Alliance | National Institute of Allergy and Infectious Diseases | Payment unspecified | 5/7/20 |
Atomwise and Dana-Farber Cancer Institute to discover an undisclosed traget treatment for COVID-19 | Dana-Farber Cancer Institute | Atomwise | Payment unspecified | 5/21/20 |
UM and Deerfield Management to form a joint venture, Great Lakes Discoveries to commercialize therapeutics for unmet indications | Deerfield Management Company LP | University of Michigan | Payment unspecified | 5/27/20 |
Certara and DMTC to evaluate chloroquine in health care workers at risk of COVID-19 | Defence Materiel Technology Centre | Certara Inc. | Payment unspecified | 5/7/20 |
DCRI to conduct clinical trial of Boehringer Ingelheim's Empagliflozin against acute myocardial infarction | Duke Clinical Research Institute | Boehringer Ingelheim International GmbH | Payment unspecified | 5/26/20 |
Emory University and Colorado State University to conduct research on STP-0404 against AIDS | Emory University | Colorado State University | Payment unspecified | 5/8/20 |
FPRF and Coda to identify and develop therapies for trigeminal neuralgia and neuropathy with chemogenetic gene therapy platform | Facial Pain Research Foundation | Coda Biotherapeutics Inc. | Payment unspecified | 5/20/20 |
Griffith University and Fraunhofer-Institute to develop COVID-19 drug | Fraunhofer-Institute of Toxicology and Experimental Medicine | Griffith University | Payment unspecified | 5/7/20 |
Bonac and Fukuoka Institute to develop RNA nucleic acid therapeutics for COVID-19 infection | Fukuoka Institute of Health and Environmental Health | Bonac Corp. | Payment unspecified | 5/18/20 |
FIB Hospital Infantil Universitario Niño Jesús to use Orgenesis’ CGT Biotech Platform to develop and manufacture cell and gene therapies against solid metastatic tumor | Fundación Para La Investigación Biomédica Del Hospital Infantil Universitario Niño Jesús | Orgenesis Inc. | Payment Unspecified | 5/22/20 |
Applied Biology and University Hospital Ramon y Cajal to study the genetics of the androgen receptor in androgenetic alopecia and severity of COVID-19 infection | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Applied Biology Inc. | Payment unspecified | 5/4/20 |
GARDP to sign an MOU with BioVersys to develop antibiotics including BV-100 for paediatric bacterial infections | Global Antibiotic Research and Development Partnership | Bioversys AG | Payment unspecified | 5/5/20 |
Hoag to conduct clinical trial for Nascent's pritumumab in glioblastoma patients | Hoag Memorial Hospital Presbyterian | Nascent Biotech Inc. | Payment unspecified | 5/21/20 |
Chemotargets and IMIM to discover and develop oncological therapies | Hospital del Mar Medical Research Institute | Chemotargets SL | Payment unspecified | 5/25/20 |
Bharat Biotech to use ICMR-NIV's virus strain to develop vaccine for COVID-19 | Indian Council of Medical Research | Bharat Biotech International Ltd. | Payment unspecified | 5/9/20 |
INRAE and Evolugate to enter an option to optimize and develop Probiotics for hypercholesterolemia | Institut National de la Recherche Agronomique | Evolugate LLC | Payment unspecified | 5/28/20 |
Instituto Butantan to develop, manufacture and marketing of Valneva's VLA-1553 against Chikungunya virus infection in LMICs | Instituto Butantan | Valneva SE | Payment unspecified | 5/5/20 |
Cytodyn and Mexican NIH to conduct clinical trial study on Leronlimab for severe/critical COVID-19 | Instituto Politecnico Nacional | Cytodyn Inc. | Payment unspecified | 5/19/20 |
IAVI and Merck to develop rVSV technology based vaccine against COVID-19 infection worldwide | International AIDS Vaccine Initiative | Merck & Co. Inc. | Payment unspecified | 5/26/20 |
Ipsen to acquire option to develop and commercialize Iricor's oncology program worldwide | Iricor | Ipsen SA | Payment unspecified | 5/4/20 |
NCC and Rakuten Medical to develop Illuminox-based cancer therapies | Japanese National Cancer Center | Rakuten Medical Inc. | Payment unspecified | 5/20/20 |
Jazan University and Atomwise to discover drug candidates targeting Spike for COVID-19 and other coronaviruses | Jazan University | Atomwise | Payment Unspecified | 5/21/20 |
Maastricht University to conduct phase IIa study for Mind Medicine's lysergic acid diethylamide against attention deficit hyperactivity disorder | Maastricht University | Mind Medicine Inc. | Payment unspecified | 5/11/20 |
Synthetic to use IP rights of MGH's intestinal alkaline phosphatase to develop SYN-020 for age-related metabolic and inflammatory diseases | Massachusetts General Hospital | Synthetic Biologics Inc. | Payment unspecified | 5/27/20 |
Ceapro and McMaster University to develop PGX-processed yeast beta-glucans as an inhalable immunomodulating therapeutic for COVID-19 patients | McMaster University | Ceapro Inc. | Payment unspecified | 5/26/20 |
MD Anderson to grant rights of 16 patent applications and related technology to Genprex for treatment of cancer | MD Anderson Cancer Center | Genprex Inc. | Payment unspecified | 5/5/20 |
Innovent Biologics and MD Anderson to develop Innovent's Tyvyt for rare cancers in the U.S. | MD Anderson Cancer Center | Innovent Biologics Inc. | Payment unspecified | 5/18/20 |
Asylia to develop MD Anderson Cancer Center's HSP70 modulators including ASY-77A against cancer, autoimmune and infectious diseases worldwide | MD Anderson Cancer Center | Asylia Therapeutics Inc. | Payment unspecified | 5/1/20 |
Medical University of Vienna to assess Apeptico's solnatide in COVID-19 patients | Medical University of Vienna | Apeptico Forschung und Entwicklung GmbH | Payment unspecified | 5/4/20 |
Miami University and Psybio to develop technology for the biosynthesis of psilocybin and other psychoactive molecules to treat depression, anxiety, PTSD, and substance dependency | Miami University (Ohio) | Psybio Therapeutics Inc. | Payment Unspecified | 5/22/20 |
Mount Sinai and Sorrento to develop COVI-SHIELD antibody cocktail therapy for COVID-19 | Mount Sinai Health System | Sorrento Therapeutics Inc. | Payment unspecified | 5/8/20 |
University of Nairobi to conduct clinical trial for University of Oxford's ChAdOx1.tHIVconsv1 vaccine for the treatment of HIV-1 infection | Nairobi University | University of Oxford | Payment unspecified | 5/14/20 |
NCATS to conduct phase II/III of Acer's emetine hydrochloride for the treatment of COVID-19 infection | National Center For Advancing Translational Sciences | Acer Therapeutics Inc. | Payment unspecified | 5/11/20 |
NCBID and Chimeron Bio to develop COVID-19 vaccine | National Center for Biodefense and Infectious Diseases | Chimeron Bio | Payment unspecified | 5/28/20 |
Immunoprecise and NIDDK to study molecuar interactions of therapeutic antibody from IPA's SARS-CoV-2 programs to treat COVID-19 | National Institute of Diabetes, Digestive and Kidney Diseases | Immunoprecise Antibodies Ltd. | Payment unspecified | 5/14/20 |
Caamtech and NIDA to enter CRADA for the research of Psychedelic tryptamine-based compounds | National Institute on Drug Abuse | Caamtech LLC | Payment unspecified | 5/7/20 |
NIH to conduct a phase II clincial study for Neurotrope's Bryostatin-1 against Alzheimer's disease | National Institutes of Health | Neurotrope Inc. | $2.70 | 5/28/20 |
Public Health Research Institute to evaluate Innovation's brilacidin against COVID-19 | New York Public Health Research Institute | Innovation Pharmaceuticals Inc. | Payment unspecified | 5/5/20 |
Oxford Vacmedix and NDM to develop recombinant peptide vaccine and diagnostic tests for COVID-19 | Nuffield Department of Clinical Medicine | Oxford Vacmedix | Payment unspecified | 5/28/20 |
Microbion and NYU Langone to settle patent litigation related to bismuth-thiol technology | NYU Winthrop Hospital | Microbion Corp. | Payment unspecified | 5/4/20 |
Quantum Leap Healthcare to evaluate Aerpio Pharmaceuticals' Razuprotafib against acute respiratory distress syndrome in COVID-19 patients | Quantumleap Healthcare | Aerpio Pharmaceuticals Inc | Payment unspecified | 5/27/20 |
Neovii to develop and commercialize COVID-19 vaccine using Tel Aviv University's patented platform technology | Ramot at Tel Aviv University Ltd. | Neovii Biotech GmbH | Payment unspecified | 5/13/20 |
Roswell Park Comprehensive Cancer Center to evaluate the effects of Rafael Pharmaceuticals' CPI-613 with or without chemotherapy agents in esophageal cancer cells | Roswell Park Comprehensive Cancer Center | Rafael Pharmaceuticals Inc. | Payment unspecified | 5/5/20 |
Santhera to use Rutgers' intellectual property related to certain gene constructs to advance gene therapy research for LAMA2-related muscular dystrophy | Rutgers University | Santhera Pharmaceuticals AG | Payment unspecified | 5/6/20 |
Xenetic Biosciences and Scripps Research to develop XCART technology against B cell malignancies | Scripps Research Institute | Xenetic Biosciences Inc. | $3.00 | 5/15/20 |
Shinshu University and Toshiba to develop tumor-tropic liposome gene delivery technology against cancer | Shinshu University | Toshiba Corp. | Payment unspecified | 5/28/20 |
Singapore General Hospital to evaluate Partner Therapeutics' Leukine in respiratory illness in patients with COVID-19 | Singapore General Hospital Pte. Ltd. | Partner Therapeutics Inc. | Payment unspecified | 5/28/20 |
Biocad to develop and commercialize State Research Center of Virology and Biotechnology's rVSV vaccine for COVID-19 | State Research Center of Virology and Biotechnology VECTOR | Biocad Ltd. | Payment unspecified | 5/12/20 |
Vaxil and Tel Aviv Medical Center to develop peptide vaccine against COVID-19 | Tel Aviv Sourasky Medical Center | Vaxil Biotherapeutics Ltd. | Payment unspecified | 5/5/20 |
Bharat Biotech to develop Jefferson University's COVID-19 vaccine worldwide, excluding the U.S., Europe and Japan | Thomas Jefferson University | Bharat Biotech International Ltd. | Payment unspecified | 5/20/20 |
Honorhealth and Tgen to initiate combinational therapy of atovaquone and azithromycin in COVID-19 clinical trial | Translational Genomics Research Institute | Honorhealth Research Institute | Payment unspecified | 5/5/20 |
UMONS to grant IP rights related to DUX4 gene to Dyne for evaluating therapies targeting genetic cause of Facioscapulohumeral muscular dystrophy | Universite De Mons | Dyne Therapeutics | Payment unspecified | 5/19/20 |
Nanomab and University Hospital Aachen to assess the therapeutic benefits of NM-02 in late stage HER2 positive breast cancer | University Hospital, Aachen | Nanomab | Payment Unspecified | 5/21/20 |
Vivazome to use intellectual property related to University of Adelaide's stem cells to develop and commercialize exosome-based therapeutics worldwide | University of Adelaide | Vivazome Therapeutics Pty Ltd. | Payment unspecified | 5/5/20 |
Tonix to use University of Alberta's technology and patents related to TNX-1810, TNX-1820 and TNX-1830 against COVID-19 | University of Alberta | Tonix Pharmaceuticals Holding Corp. | Payment unspecified | 5/7/20 |
University of Connecticut and Atomwise to discover drug candidates targeting NSP15 for COVID-19 and other coronaviruses | University of Connecticut | Atomwise | Payment Unspecified | 5/21/20 |
University of Kentucky and Atomwise to discover drug candidates targeting PLpro for COVID-19 and other coronaviruses | University of Kentucky | Atomwise | Payment Unspecified | 5/21/20 |
University of Manitoba and Atomwise to discover drug candidates targeting IL-6 Signaling and RdRp in NSP12 for COVID-19 and other coronaviruses | University of Manitoba | Atomwise | Payment Unspecified | 5/21/20 |
University of Newcastle to conduct preclinical research of Race Oncology's bisantrene hydrochloride agaisnt acute myeloid leukemia | University of Newcastle | Race Oncology Ltd. | Payment unspecified | 5/14/20 |
Cue Biopharma and University of Oxford to research on CUE-100 series against solid and hematological cancers | University of Oxford | Cue Biopharma Inc. | Payment unspecified | 5/14/20 |
Prescient Therapeutics to use University of Oxford's Spytag/Spycatcher molecular binding system to develop CAR-T cell therapies against cancer | University of Oxford | Prescient Therapeutics Ltd. | Payment unspecified | 5/26/20 |
Passage Bio expanded its collaboration agreement with the University of Pennsylvania to include an additional five programs and extending Passage Bio’s period to exercise new programs through 2025 | University of Pennsylvania | Passage Bio Inc. | Payment unspecified | 5/7/20 |
Prescient Therapeutics to use University of Pennsylvania's immune receptor platform to develop CAR-T cell therapies against cancer worldwide | University of Pennsylvania | Prescient Therapeutics Ltd. | Payment unspecified | 5/26/20 |
University of South Australia and Atomwise to discover drug candidates targeting Spike-ACE2 for COVID-19 and other coronaviruses | University of South Australia | Atomwise | Payment Unspecified | 5/21/20 |
University of Southern California and Shanghai Cell Therapy Group to develop conditions for ex vivo expansion of mouse and human hematopoietic stem and progenitor cells for cancers and blood diseases | University of Southern California | Shanghai Cell Therapy Group Co. Ltd. | Payment unspecified | 5/27/20 |
University of Texas and Atomwise to discover an undisclosed target against COVID-19 using artificial intelligence technology | University of Texas Health Science Center San Antonio | Atomwise | Payment unspecified | 5/21/20 |
University of Toledo to develop therapies for undisclosed target against COVID-19 using Atomwise's artificial intelligence technology | University of Toledo | Atomwise | Payment unspecified | 5/21/20 |
Virna Therapeutics to develop University of Toronto's neutralizing antibodies against COVID-19 | University of Toronto | Virna Therapeutics Inc. | Payment unspecified | 5/27/20 |
University of Toronto to evaluate the effects of Amarin's Vascepa in the treatment of COVID-19 patients | University of Toronto | Amarin Corp. plc | Payment unspecified | 5/21/20 |
Acadia to develop and commercialize Vanderbilt University's drug candidates targeting the muscarinic M1 receptor for central nervous system disorders worldwide | Vanderbilt University | Acadia Pharmaceuticals Inc. | $525.00 | 5/7/20 |
Idbiologics and Vanderbilt University Medical Center to develop novel monoclonal antibody medicines for COVID-19 | Vanderbilt University Medical Center | Idbiologics | Payment unspecified | 5/7/20 |
Zyus and Vido-Intervac to develop a plant-based vaccine for COVID-19 infection | Vido-Intervac | Zyus Life Sciences Inc. | Payment unspecified | 5/7/20 |
Hoth Therapeutics to use VCU's technology and IP to develop peptide therapeutic for COVID-19 worldwide | Virginia Commonwealth University | Hoth Therapeutics Inc. | Payment unspecified | 5/18/20 |
Waisman to manufacture Heat Biologics' COVID-19 vaccine for phase I clinical trial | Waisman Clinical Biomanufacturing Facility | Heat Biologics Inc. | Payment unspecified | 5/27/20 |
Iqvia and Walter and Eliza Hall Institute to conduct COVID SHIELD, a phase II/III to test the generic Hydroxychloroquine as a prophylactic treatment to prevent COVID-19 | Walter and Eliza Hall Institute of Medical Research | Iqvia Holdings Inc. | Payment unspecified | 5/20/20 |
Cytosurge and Wyss Institute to develop CRISPR-multiplexed gene editing approaches to maintain cell viability using FluidFM technology | Wyss Institute for Biologically Inspired Engineering | Cytosurge Ag | Payment unspecified | 5/4/20 |
4D Molecular Therapeutics and Cystic Fibrosis Foundation to develop precision gene medicines for cystic fibrosis | 4D Molecular Therapeutics Inc. | Cystic Fibrosis Foundation | $14.00 | 6/17/20 |
MedAnnex and Anglia Ruskin University to develop therapeutic candidates against cancer | Anglia Ruskin University | Medannex Ltd. | Payment unspecified | 6/15/20 |
Astrazeneca to supply COVID-19 vaccine to EU governments | Astrazeneca plc | The European Union | $829.20 | 6/15/20 |
AstraZeneca to supply COVID-19 vaccine to Inclusive Vaccines Alliance | Astrazeneca plc | The European Union | Payment unspecified | 6/13/20 |
Medsintez to join Bioorganika Consortium to develop and produce analogs for diabetes and blood coagulation disorders | Bioorganika Consortium | Medsintez | Payment unspecified | 6/17/20 |
Microbiotica and Cancer Research UK to identify and develop microbiome co-therapeutics and biomarkers for cancer | Cancer Research UK | Microbiotica Ltd. | Payment unspecified | 6/8/20 |
Scopus to develop and commercialize the City of Hope's CpG-STAT3siRNA for cancer, including B cell lymphoma worldwide | City of Hope | Scopus Biopharma Inc. | Payment unspecified | 6/11/20 |
CEPI to manufacture and supply Astrazeneca's AZD-1222 for COVID-19 infection | Coalition for Epidemic Preparedness Innovations | Astrazeneca plc | $750.00 | 6/4/20 |
CSL, CEPI and the University of Queensland to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate | Coalition for Epidemic Preparedness Innovations | CSL Ltd. | Payment unspecified | 6/9/20 |
Columbia University and Ovid Therapeutics to advance the development of genetic-based therapies for rare neurological conditions | Columbia University Irving Medical Center | Ovid Therapeutics Inc. | Payment unspecified | 6/11/20 |
CSIRO and Immuron to develop a hyper-immune bovine colostrum product against campylobacteriosis and enterotoxigenic Escherichia coli infections | Commonwealth Scientific and Industrial Research Organization | Immuron Ltd. | Payment unspecified | 6/19/20 |
DSRU and University of Dundee to form consortium to monitor the safety and effectiveness of COVID-19 vaccines | Drug Safety Research Unit, Southampton | University of Dundee | Payment unspecified | 6/25/20 |
Frederick National Laboratory to develop Dyadic's patented C1 cell lines to develop COVID-19 vaccine candidates | Dyadic International Inc. | Frederick National Laboratory for Cancer Research | Payment unspecified | 6/10/20 |
Edith Wolfson Medical Center to conduct clinical study for Orgenesis' POCare Technologies against adoptive T-cell therapies in cancer | Edith Wolfson Medical Center | Orgenesis Inc. | Payment unspecified | 6/1/20 |
Aligos Therapeutics expanded its licensing agreement with Emory University to include and advance technology related to capsid assembly modulator program in chronic hepatitis B | Emory University | Aligos Therapeutics Inc. | Payment unspecified | 6/23/20 |
European Vaccine Initiative to provide development services to Mymetics' CoV RBD219-N1 for COVID-19 infection | European Vaccine Initiative | Mymetics Corp. | Payment unspecified | 6/11/20 |
Fiocruz to produce Astrazeneca’s vaccine against coronavirus in Brazil | Fundacao Oswaldo Cruz (Fiocruz) | AstraZeneca plc | $127.00 | 6/28/20 |
Hoth Therapeutics expanded its sponsored research agreement with George Washington University to explore WEG-232 for topical and/or systemic therapy to counter dermatological side effects of chemotherapy and immunotherapy in cancer patients | George Washington University | Hoth Therapeutics Inc. | Payment unspecified | 6/16/20 |
GAVI to manufacture and supply Astrazeneca's AZD-1222 for COVID-19 infection | Global Alliance for Vaccines and Immunization | Astrazeneca plc | Payment unspecified | 6/4/20 |
GNS Healthcare and MMRF to discover novel treatments for multiple myeloma | GNS Healthcare Inc. | Multiple Myeloma Research Foundation | Payment unspecified | 6/18/20 |
Algiax to investigate Heinrich Heine University's HK-4 for the treatment of diabetes mellitus | Heinrich Heine Universitat Dusseldorf | Algiax Pharmaceuticals GmbH | Payment unspecified | 6/13/20 |
Horae Gene Therapy and Canbridge Pharmaceuticals to initiate research on a gene therapy program in rare genetic diseases | Horae Gene Therapy Center | Canbridge Life Sciences Ltd. | Payment unspecified | 6/9/20 |
Houston Methodist Hospital to conduct a phase II clinical trial for Relief's RLF-100 against acute and moderate respiratory distress in COVID-19 | Houston Methodist Hospital | Relief Therapeutics Holding AG | Payment unspecified | 6/11/20 |
Imperial College London to evaluate Trevena's TRV-027 for ARDS in COVID-19 patients | Imperial College London | Trevena Inc. | Payment unspecified | 6/2/20 |
INRS and Glycovax to develop vaccine against COVID-19 | Institut National De La Recherche Scientifique | Glycovax Pharma Inc. | Payment unspecified | 6/17/20 |
Institut Pasteur of Shanghai and Alphamab Oncology to manufacture, develop and commercialize COVID-19 neutralizing antibody worldwide | Institut Pasteur of Shanghai Chinese Academy of Sciences | Jiangsu Alphamab Biopharmaceuticals Co. Ltd. | Payment unspecified | 6/10/20 |
INGEMM and Oryzon Genomics to develop vafidemstat for Phelan-McDermid syndrome | Institute of Medical and Molecular Genetics of the La Paz University Hospital | Oryzon Genomics SA | Payment unspecified | 6/19/20 |
Instituto Butantan to conduct a phase III clinical study of Sinovac's Coronavac against COVID-19 | Instituto Butantan | Sinovac Biotech Ltd. | Payment unspecified | 6/11/20 |
Versatope to develop VT-105 with Intravacc's OMV technology against Influenza | Intravacc | Versatope Therapeutics Inc. | Payment unspecified | 6/8/20 |
TB Alliance to use Inveniai's Alphameld platform to identify and develop transformative therapies for the treatment of tuberculosis | Inveniai Corp. | TB Alliance | Payment unspecified | 6/2/20 |
Guangzhou Lixin to develop and commercialize Jinan University's JND-32066 against cancer | Jinan University (Guangdong) | Guangzhou Lixin Pharmaceuticals | $14.22 | 6/8/20 |
Goethe University and Boehringer Ingelheim to form consortium to develop chemical tool compounds for immunology, oncology and neuroscience diseases | Johann Wolfgang Goethe-Universitat Frankfurt am Main | Boehringer Ingelheim International GmbH | Payment unspecified | 6/8/20 |
Bridgebio and JHU to accelerate development of medicines in genetically driven diseases | Johns Hopkins University | Bridgebio Pharma Inc. | Payment unspecified | 6/18/20 |
Oncolys Biopharma to acquire patent rights from Kagoshima University related to anti-viral activity on SARS-CoV-2 virus to treat COVID-19 | Kagoshima University | Oncolys Biopharma Inc. | Payment unspecified | 6/19/20 |
Legochem to develop Korea Research Institute of Chemical Technology's two COVID-19 treatment candidates | Korea Research Institute of Chemical Technology | Legochem Bioscience Inc. | Payment unspecified | 6/9/20 |
Inno.N to develop Korea Research Institute of Chemical Technology's COVID-19 vaccine | Korea Research Institute of Chemical Technology | Inno.N Corp. | Payment unspecified | 6/9/20 |
LSK to support phase I/II clinical trial for IVI's INO-4800 vaccine against COVID-19 infection in Korea | LSK Global Pharma Services Co. Ltd. | International Vaccine Institute | Payment unspecified | 6/17/20 |
Egenesis and MGH to conduct in vivo testing of lead kidney and islet xenotransplant programs and validate platform in other organs | Massachusetts General Hospital | Egenesis Inc. | Payment unspecified | 6/2/20 |
adMare and McGill University to advance made-in-Canada research to provide opiate-sparing pain-relieving drugs | McGill University | Admare Bioinnovations | Payment unspecified | 6/4/20 |
MD Anderson and Rakuten Medical to develop Illuminox-based cancer therapies | MD Anderson Cancer Center | Rakuten Medical Inc. | Payment unspecified | 6/4/20 |
Minerva to use MSK's 1XX technology in anti-MUC1* antibodies to increase CAR-T cell persistence and function in cancer patients | Memorial Sloan-Kettering Cancer Center | Minerva Biotechnologies Corp. | Payment unspecified | 6/22/20 |
Moderna to supply COVID-19 vaccine to the Israeli Government | Moderna Therapeutics | Israeli Government | Payment unspecified | 6/17/20 |
Monash University and Burnet Institute to evaluate antiviral activity of peptides against COVID-19 | Monash University | The Macfarlane Burnet Institute For Medical Research & Public Health Ltd. | Payment unspecified | 6/3/20 |
Keio University and NCGHM to develop a mucosal vaccine against COVID-19 | National Center For Global Health & Medicine | Keio University | Payment unspecified | 6/30/20 |
NMDP to advance development of Magenta's MGTA-145 for mobilization of stem cells from donors and subsequent transplant in leukemia patients | National Marrow Donor Program | Magenta Therapeutics Inc. | Payment unspecified | 6/11/20 |
Berg Pharma to use ORNL's Summit supercomputer for drug discovery against COVID-19 | Oak Ridge National Laboratory | Berg Pharma LLC | Payment unspecified | 6/17/20 |
Quantum Leap Healthcare to conduct I-SPY 2 study for Sanofi's SAR-439859 against breast cancer | Quantumleap Healthcare | Sanofi SA | Payment unspecified | 6/8/20 |
Ragon Institute to evaluate Codiak Biosciences' exovacc platform for the development of vaccine against SARS-CoV-2 and HIV | Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard | Codiak Biosciences Inc. | Payment unspecified | 6/1/20 |
Royal Philips to provide informatics solutions with MD Anderson's PODS for patient treatment against cancer | Royal Philips Electronics | MD Anderson Cancer Center | Payment unspecified | 6/16/20 |
RDIF and R-Pharm to form joint venture to develop vaccine including Artlegia and RPH-104 against COVID-19 infection | R-Pharm | Russian Direct Investment Fund | Payment unspecified | 6/10/20 |
Sanford-Burnham and Eli Lilly to evaluate next-generation anti-SARS-CoV-2 antibodies | Sanford-Burnham Medical Research Institute | Eli Lilly and Co. | Payment unspecified | 6/29/20 |
SRI and Repurpose AI to discover drug candidates against COVID-19 using ActivPred AI Drug Discovery Platform | Scripps Research Institute | Repurpose AI Inc. | Payment unspecified | 6/23/20 |
CSL Behring and Seattle Children's Research Institute to develop stem cell gene therapies for primary immunodeficiency diseases | Seattle Children's Hospital | CSL Behring LLC | Payment unspecified | 6/2/20 |
Seoul National to conduct phase I/II trial of Inovio's INO-4800 vaccine against COVID-19 infection in South Korea | Seoul National University Hospital | Inovio Pharmaceuticals Inc. | Payment unspecified | 6/4/20 |
Tonix Pharmaceuticals expanded its collaboration with Southern Research to include a study of T-cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19 | Southern Research | Tonix Pharmaceuticals Holding Corp. | Payment unspecified | 6/18/20 |
Artelo expanded the agreement and obtained exclusive rights to third generation FABP5 inhibitors and plans to select a cancer compound and to identify additional candidates for pain, inflammation and other conditions | State University of New York | Artelo Biosciences Inc. | Payment unspecified | 6/29/20 |
Intravacc and Wageningen Bioveterinary Research to develop intranasal vaccine against COVID-19 | Stichting Wageningen Research (Wageningen Bioveterinary Research (Wbvr)) | Intravacc | Payment unspecified | 6/4/20 |
SAKK to conduct clinical trial on Oasmia’s docetaxel micellar compound for advanced prostate cancer | Swiss Group for Clinical Cancer Research | Oasmia Pharmaceutical AB | Payment unspecified | 6/8/20 |
University of Birmingham to conduct a catlyst clinical trial of Celltrion's CT-P13 against inflammation caused by COVID-19 | The University of Birmingham | Celltrion Healthcare Co. Ltd. | Payment unspecified | 6/10/20 |
University of Liverpool and University of Utrecht to develop a viable drug based on teixobactin for multi-drug resistant bacterial pathogens | The University of Liverpool | Universiteit Utrecht | Payment unspecified | 6/5/20 |
U.S. Government to conduct a phase I clinical trial of AstraZeneca's SARS-CoV-2 virus-neutralizing mAb's against COVID-19 | U.S. Government | Astrazeneca plc | Payment unspecified | 6/9/20 |
Servier and Autonomous University of Barcelona to identify and develop therapeutic candidates for neurodegenerative diseases | Universitat Autonoma de Barcelona | Servier | Payment unspecified | 6/30/20 |
Abbvie to develop Universiteit Utrecht's monoclonal antibody against COVID-19 worldwide | Universiteit Utrecht | Abbvie Inc. | Payment unspecified | 6/5/20 |
MindMed to use University Hospital Basel's patent applications to optimize dosing of MDMA and LSD and other psychedelics including 18-methoxycoronaridine for opioid disorder | University Hospital Basel | Mind Medicine Inc. | Payment unspecified | 6/24/20 |
CBHI and UAMS to study the efficacy of SAC in patients with multiple myeloma and erythropoietin-included osteoporosis | University of Arkansas for Medical Sciences | Calcium and Bone Health Institute | Payment unspecified | 6/10/20 |
UAMS to conduct clinical study for Kiyatec's test in patients with ovarian cancer drugs | University of Arkansas for Medical Sciences | Kiyatec LLC | Payment unspecified | 6/25/20 |
UC Davis to evaluate Avectas' Solupore technology using cell membrane characterization expertise and assays for cell therapies | University of California Davis | Avectas Ltd. | Payment unspecified | 6/3/20 |
Autobahn and UCLA to perform drug discovery and development | University of California Los Angeles | Autobahn Labs LLC | Payment unspecified | 6/24/20 |
Vault Pharma and the University of California, Los Angeles, and other universities to advance a vaccine to treat SARS-CoV-2 | University of California, Los Angeles | Vault Pharma Inc. | Payment unspecified | 6/4/20 |
University of Dundee and Evgen to investigate SFX-01 in a clinical trial against COVID-19 | University of Dundee | Evgen Pharma plc | Payment unspecified | 6/17/20 |
Bridgebio Pharma and University of Florida to develop and commercialize gene therapy against rare and genetic disease | University of Florida | Bridgebio Pharma Inc. | Payment unspecified | 6/18/20 |
Modular Bioscience to acquire intellectual property rights related to artificial restriction enzyme technology from University of Illinois for diagnosing various indications, including COVID-19 worldwide | University of Illinois at Urbana-Champaign | Modular Bioscience Inc. | Payment unspecified | 6/2/20 |
KUMC to conduct to evaluate Aclaris’ ATI-45 in hospitalized patients with COVID-19 | University of Kansas Medical Center | Aclaris Therapeutics Inc | Payment unspecified | 6/17/20 |
University of Kentucky and Artemilife to conduct clinical study to evaluate Artemisia annua for anti-cancer activity and recommended dose | University of Kentucky | Artemilife Inc. | Payment unspecified | 6/4/20 |
Qualigen to use University of Louisville' technology or patents to develop AS-1411 against COVID-19 | University of Louisville | Qualigen Therapeutics Inc. | Payment unspecified | 6/10/20 |
University of Michigan to conduct preclinical studies for Cereno Scientific's HDACi program against cardiovascular and rare diseases | University of Michigan | Cereno Scientific AB | Payment unspecified | 6/9/20 |
BioArctic and University of Oslo to study ApoE as a target for Alzheimer's disease | University of Oslo | Bioarctic AB | Payment unspecified | 6/29/20 |
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo to develop nafamostat inhalation against COVID-19 | University of Tokyo | Daiichi Sankyo Co. Ltd. | Payment unspecified | 6/8/20 |
Revive Therapeutics expanded its partnership with the University of Wisconsin-Madison to evaluate novel formulations of psilocybin for an undisclosed addiction use disorder | University of Wisconsin-Madison | Revive Therapeutics Ltd. | Payment unspecified | 6/12/20 |
Astrazeneca to develop Vanderbilt University's monoclonal antibodies for the prevention and treatment of COVID-19 | Vanderbilt University | Astrazeneca plc | Payment unspecified | 6/10/20 |
Astrazeneca to develop Vanderbilt University's monoclonal antibodies for the prevention and treatment of COVID-19 | Vanderbilt University | Astrazeneca plc | Payment unspecified | 6/10/20 |
Giostar to enter into memorandum of understanding to use Vitro's AlloRx stem cells in the treatment of COVID-19 | Vitro Diagnostics Inc. | Giostar | Payment unspecified | 6/2/20 |
DARPA and Wyss Institute to identify and test FDA-approved drugs as repurposed drugs to prevent or treat COVID-19 | Wyss Institute for Biologically Inspired Engineering | Defense Advanced Research Projects Agency | $16.00 | 6/16/20 |
Aichi Cancer Center and NEC to develop neantigen vaccine for cancer | Aichi Cancer Center Central Hospital | NEC Corp. | Payment unspecified | 7/6/20 |
Alfred Hospital to conduct phase II trial for Incannex’s IHL-42X in obstructive sleep apnoea patients | Alfred Hospital | Incannex Pty Ltd. | Payment unspecified | 7/9/20 |
Arcturus to supply LUNAR-COV19 to Israeli Government | Arcturus Therapeutics Inc. | Israeli Government | Payment unspecified | 7/23/20 |
Mateon and Asili Research to conduct observational study for artemisinin against COVID-19 | Asili Research Alliance | Mateon Therapeutics Inc. | Payment unspecified | 7/20/20 |
Fate Therapeutics and BCM to develop rejection-resistant iPSC-derived cellular therapies against cancer | Baylor College of Medicine | Fate Therapeutics Inc. | Payment unspecified | 7/14/20 |
Beijing Tiantan to conduct phase I/IIa trial for Jiuzhitang's it-hMSC in ischemic stroke patients of China | Beijing Tiantan Hospital | Jiuzhitang Maker (Beijing) Cell Technology Co. Ltd. | Payment unspecified | 7/6/20 |
Pfizer and Biontech to supply U.K. Government with mRNA-based vaccine, BNT-162 against COVID-19 | Biontech SE | U.K. Government | Payment unspecified | 7/20/20 |
Biontech to supply U.S. Government with mRNA-based vaccine, BNT-162 against COVID-19 | Biontech SE | U.S. Department of Health and Human Services | $1,950.00 | 7/22/20 |
Pfizer and Biontech to supply MHLW with mRNA-based vaccine, BNT-162 against COVID-19 | Biontech SE | Japanese Ministry of Health, Labor and Welfare | Payment unspecified | 7/31/20 |
Cancer Research UK and Abcam to develop and commercialize custom based antibody reagents for cancer research | Cancer Research UK | Abcam plc | Payment unspecified | 7/7/20 |
Celonic and Intravacc to develop and produce COVID-19 vaccine with Intravacc's OMV technology | Celonic AG | Intravacc | Payment unspecified | 7/29/20 |
Changchun Zhuoyi Biological to develop Chinese Academy of Medical Science's universal human papillomavirus vaccine | Chinese Academy of Medical Sciences & Peking Union Medical College | Changchun Zhuoyi Biological Co. Ltd. | Payment unspecified | 7/16/20 |
Intravacc to use Cimcure's iboost Technology to develop vaccines against cancer and COVID-19 | Cimcure | Intravacc | Payment unspecified | 7/1/20 |
TGen and City of Hope to create personalized roadmaps for the treatment of kidney cancer | City of Hope | Translational Genomics Research Institute | Payment unspecified | 7/22/20 |
Cleveland Clinic and Celsius Therapeutics to evaluate Crohn’s disease patients who develop disease recurrence following intestinal resection | Cleveland Clinic Foundation | Celsius Therapeutics Inc. | Payment unspecified | 7/1/20 |
Tonix Pharmaceuticals and Columbia University to develop precision medicine techniques for COVID-19 vaccines and therapeutics | Columbia University | Tonix Pharmaceuticals Holding Corp. | Payment unspecified | 7/16/20 |
Kedrion Biopharma and Columbia University to develop and test IgG therapy for COVID-19 | Columbia University Irving Medical Center | Kedrion Biopharma Inc. | Payment unspecified | 7/20/20 |
Liminal Bioscience to join CoVIg-19 Plasma Alliance to develop plasma-derived therapy for COVID-19 | CoVIg-19 Plasma Alliance | Liminal BioSciences Inc. | Payment unspecified | 7/2/20 |
Mount Sinai Health to manufacture, develop and evaluate the Emergent Biosolutions' COVID-HIG against COVID-19 | Emergent Biosolutions Inc. | Mount Sinai Health System | Payment unspecified | 7/8/20 |
Fujifilm to manufacture vaccine to support BARDA’s COVID-19 program | Fujifilm Diosynth Biotechnologies Texas LLC | U.S. Department of Health and Human Services | Payment unspecified | 7/27/20 |
Groupe Francophone to conduct phase II study of Biosight's BST-236 against relapsed or refractory myelodysplastic syndrome and acute myeloid leukemia | Groupe Francophone des Myelodysplasies | Biosight Ltd. | Payment unspecified | 7/21/20 |
Hackensack Meridian Center and Merck to identify drug candidates for COVID-19 | Hackensack Meridian Health | Merck & Co. Inc. | Payment unspecified | 7/14/20 |
Vesigen to develop and commercialize Harvard’s drug delivery technologies | Harvard TH Chan School of Public Health | Vesigen Therapeutics Inc. | Payment unspecified | 7/22/20 |
Amyris and IDRI to develop RNA vaccine against COVID-19 | Infectious Disease Research Institute | Amyris Inc. | Payment unspecified | 7/27/20 |
Gustave Roussy to conduct research studies on Daiichi's DS-1062 for non-small-cell lung carcinoma and U3-1402 for breast cancer | Institut Gustave Roussy | Daiichi Sankyo Co. Ltd. | Payment unspecified | 7/22/20 |
IAVI and Scripps research to develop HIV bnAb combination injections for AGYW in LMIC countries | International AIDS Vaccine Initiative | Scripps Research Institute | Payment unspecified | 7/9/20 |
Axoprotego to develop and commercialize Johns Hopkins’ ethoxyquin, including EQ-6 against chemotherapy-induced peripheral neuropathy worldwide | Johns Hopkins University | Axoprotego Therapeutics Inc. | Payment unspecified | 7/27/20 |
Tonix to use Kansas State University's intellectual property and related vaccines, including TNX-2300 against COVID-19 | Kansas State University | Tonix Pharmaceuticals Holding Corp. | Payment unspecified | 7/13/20 |
NCI to enter CRADA with Karyopharm to advance Xpovio research for various oncology indications | Karyopharm Therapeutics Inc. | National Cancer Institute | Payment unspecified | 7/17/20 |
Aligos Therapeutics and KU Leuven to develop a coronavirus protease inhibitor against COVID-19 infection | Katholieke Universiteit Leuven | Aligos Therapeutics Inc. | Payment unspecified | 7/1/20 |
Lynk Pharmaceuticals and Kobe University to develop RAS inhibitors against cancer | Kobe University | Lynk Pharmaceuticals Co. Ltd. | Payment unspecified | 7/27/20 |
Theragen Bio and KRICT to conduct research on developing a new coronavirus (COVID-19) genomic big data | Korea Research Institute of Chemical Technology | Theragen Inc. | Payment unspecified | 7/28/20 |
Leiden University Medical Center to conduct clinical trial for Neuropharm's psilocybin against posttraumatic stress disorder in veterans | Leiden University Medical Center | Neuropharm | Payment unspecified | 7/16/20 |
Advanced Biodesign and Luxembourg Institute of Health to perform research of therapeutics against tumor resistance | Luxembourg Institute of Health | Advanced Biodesign SAS | Payment unspecified | 7/1/20 |
Biogen to develop and commercialize Massachusetts' AAV-mediated gene augmentation therapy against retinitis pigmentosa worldwide | Massachusetts Eye & Ear Infirmary | Biogen Inc. | Payment unspecified | 7/6/20 |
Massachusetts General Hospital to conduct clinical trials for Kaleido Biosciences' KB-109 against COVID-19 | Massachusetts General Hospital | Kaleido Biosciences Inc. | Payment unspecified | 7/23/20 |
Cullinan Amber to license the Massachusetts Institute of Technology's anticancer therapeutics | Massachusetts Institute of Technology | Cullinan Amber | Payment unspecified | 7/22/20 |
Sanofi and MD Anderson Cancer Center to develop targeted and immune-therapies for cancer patients | MD Anderson Cancer Center | Sanofi SA | Payment unspecified | 7/14/20 |
Dynavax and Mount Sinai to develop a Universal influenza vaccine with CpG 1018 adjuvant | Mount Sinai School of Medicine | Dynavax Technologies Corp. | Payment unspecified | 7/16/20 |
Healx and Muscular Dystrophy to discover and develop therapies for facioscapulohumeral muscular dystrophy | Muscular Dystrophy UK | Healx Ltd. | Payment unspecified | 7/15/20 |
NIAID to conduct phase II/III trial of Regeneron's REGN-COV2 for the treatment of COVID-19 infection | National Institute of Allergy and Infectious Diseases | Regeneron Pharmaceuticals Inc. | Payment unspecified | 7/6/20 |
NIAID to evaluate Humanigen's lenzilumab in combination with remdesivir against COVID-19 | National Institute of Allergy and Infectious Diseases | Humanigen Inc. | Payment unspecified | 7/27/20 |
NIID and Shionogi to perform research on AIM's Ampligen against COVID-19 | National Institute of Infectious Diseases Japan | AIM Immunotech Inc. | Payment unspecified | 7/6/20 |
National Institute of Neurological Disorders and Stroke to develop Metvital’s AEO for refractory epilepsy | National Institute of Neurological Disorders and Stroke | Metvital Inc. | Payment unspecified | 7/24/20 |
NYU Grossman School of Medicine to study the effect of Reata's bardoxolone methyl in COVID-19 patients | NYU Langone Health | Reata Pharmaceuticals Inc. | Payment unspecified | 7/28/20 |
Ology Bioservices to manufacture vaccines for Department of Defense to support clinical trails | Ology Bioservices Inc. | U.S. Department of Defense | $16.30 | 7/7/20 |
C3i to develop and commercialize the OIRM's stem cell regenerative medicine | Ontario Institute for Regenerative Medicine | Centre for Commercialisation of Cancer Immunotherapy | Payment unspecified | 7/29/20 |
Eisai and Osaka University to develop a TLR 7/8 inhibitor, E-6742 against systemic lupus erythematosus | Osaka University | Eisai Co. Ltd. | Payment unspecified | 7/10/20 |
BARDA to procure Regeneron Pharmaceuticals' REGN-EB3 for Ebola virus | Regeneron Pharmaceuticals Inc. | U.S. Biomedical Advanced Research and Development Authority | $345.00 | 7/29/20 |
AIM to support Roswell's phase I/II a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 | Roswell Park Comprehensive Cancer Center | AIM Immunotech Inc. | Payment unspecified | 7/9/20 |
Sanofi to supply COVID-19 vaccine to U.K. government | Sanofi SA | U.K. Government | $624.00 | 7/5/20 |
Scilifelab and Medivir to discover and identify putative inhibitors for COVID-19 | Science For Life Laboratory | Medivir AB | Payment unspecified | 7/6/20 |
Syracuse University to develop Nascent Biotech's pritumumab against COVID-19 | Syracuse University | Nascent Biotech Inc. | Payment unspecified | 7/28/20 |
Orphazyme to join MJFF's Parkinson's Disease Research Tools consortium to develop arimoclomol for PD | The Michael J. Fox Foundation | Orphazyme ApS | Payment unspecified | 7/17/20 |
Peter Doherty Institute and Prescient to identify two programs for SARS-CoV-2 infections | The Peter Doherty Institute for Infection and Immunity | Prescient Therapeutics Ltd. | Payment unspecified | 7/21/20 |
University Health Network to perform research on Aptahem’s Apta-1 against COVID-19 | The University Health Network | Aptahem AB | Payment unspecified | 7/9/20 |
University Health Network to conduct clinical trial for Radient Technologies' biou products against pain, sleep and anxiety issues | The University Health Network | Radient Technologies Inc. | Payment unspecified | 7/17/20 |
HKUMed and Institut Pasteur to develop abiotic cubane chemistries in a nucleic acid aptamer against malaria diagnosis | The University of Hong Kong | Institut Pasteur | Payment unspecified | 7/16/20 |
University Hospital Munich and Celsius to evaluate children with very early onset inflammatory bowel disease | University Hospital Munich | Celsius Therapeutics Inc. | Payment unspecified | 7/1/20 |
Ovid and UConn to develop genetic therapy in combination with OV-101 for Angelman syndrome | University of Connecticut School of Medicine | Ovid Therapeutics Inc. | Payment unspecified | 7/23/20 |
Qualigen Therapeutics to license University of Louisville's intellectual property covering the RAS-F family of RAS oncogene protein-protein interaction inhibitor small-molecule drug candidates | University of Louisville | Qualigen Therapeutics Inc. | Payment unspecified | 7/22/20 |
UNMC to conduct phase I/II clinical trial on Covaxx' multitope peptide-based vaccine for COVID-19 | University of Nebraska Medical Center | Covaxx | Payment unspecified | 7/15/20 |
University of Nottingham and Cyanetics to conduct research and discover antiviral medication for the treatment of COVID-19 | University of Nottingham | Cyanetics Ltd. | Payment unspecified | 7/22/20 |
University of Oxford and Celsius to evaluate a large number of longitudinal samples who respond to or fail anti-TNF? therapy | University of Oxford | Celsius Therapeutics Inc. | Payment unspecified | 7/1/20 |
USF Health TCOP and Morphogenesis to perform research on immunotherapies for cancer | University of South Florida | Morphogenesis Inc. | Payment unspecified | 7/15/20 |
Cancer Research UK and University of Southampton to develop Touchlight Genetics' TGL-100 for head and neck squamous cell carcinoma | University of Southampton | Touchlight Genetics Ltd. | Payment unspecified | 7/29/20 |
Absolute Antibody and University of Zurich to develop SARS-CoV-2 sybodies against SARS-CoV-2 RBD worldwide | University of Zurich | Absolute Antibody | Payment unspecified | 7/8/20 |
Walter and Eliza Hall Institute of Medical Research and Axxin to develop c-FIND test for infections | Walter and Eliza Hall Institute of Medical Research | Axxin Pty Ltd. | Payment unspecified | 7/1/20 |
Pluristem Therapeutics and Abu Dhabi Stem Cells Center to develop and cell therapies and regenerative medicine for COVID-19 | Abu Dhabi Stem Cells Center | Pluristem Therapeutics Inc. | Payment unspecified | 8/17/20 |
Astrazeneca to supply COVID-19 vaccine to the Brazilian Government | Astrazeneca plc | Brazilian Government | $360.00 | 8/12/20 |
Astrazeneca to supply COVID-19 vaccine to European Commission | Astrazeneca plc | European Commission | Payment unspecified | 8/14/20 |
Australian Government to produce and distribute Astrazeneca’s AZD-1222 against COVID-19 | Astrazeneca plc | Australian Government | Payment unspecified | 8/19/20 |
Biological E to develop Baylor College of Medicine's COVID-19 vaccine worldwide | Baylor College of Medicine | Biological E Ltd. | Payment unspecified | 8/13/20 |
Bill & Melinda to conduct a study on Catabasis' CAT-5571 against tuberculosis | Bill & Melinda Gates Medical Research Institute | Catabasis Pharmaceuticals Inc. | Payment unspecified | 8/4/20 |
Biontech to supply Canadian Government with BNT-162, mRNA-based vaccine candidate against COVID-19 | Biontech SE | Canadian Government | Payment unspecified | 8/5/20 |
Bryologyx to enter CRADA with NCI to conduct phase I clinical trial for Bryostatin-1 in CD22 expressing acute lymphoblastic leukemia and lymphoma patients | Bryologyx Inc. | National Cancer Institute | Payment unspecified | 8/4/20 |
Cleveland Clinic to initiate an investigator-initiated study of AcelRx Pharmaceuticals' Dsuvia for post-operative recovery from orthopedic surgery | Cleveland Clinic Foundation | Acelrx Pharmaceuticals Inc. | Payment unspecified | 8/24/20 |
IsoPlexis and Columbia University to advance COVID-19 vaccine development | Columbia University | Isoplexis Corp. | Payment unspecified | 8/14/20 |
Oncolys Biopharma and Cornell University to initiate OBP-301's phase II clinical trial for head and neck cancer | Cornell University | Oncolys Biopharma Inc. | Payment unspecified | 8/7/20 |
Hifibio and Covic to develop neutralizing antibodies against COVID-19 | Coronavirus Immunotherapy Consortium | Hifibio | Payment unspecified | 8/17/20 |
Curevac to supply COVID-19 vaccine to European Commission in Europe | Curevac AG | European Commission | Payment unspecified | 8/20/20 |
Japan AMED and Daiichi Sankyo to develop DS-5670 for COVID-19 | Daiichi Sankyo Co. Ltd. | Japan Agency for Medical Research and Development | Payment unspecified | 8/31/20 |
Dalton Chemical to provide manufacturing services to develop Vido-Intervac's COVID-19 vaccine | Dalton Pharma Services | Vido-Intervac | Payment unspecified | 8/27/20 |
Genecentric and Erasmus University to identify RNA-based drug response markers and targeted therapies for non-muscle invasive bladder cancer | Erasmus University Medical Center Rotterdam | Genecentric Therapeutics | Payment unspecified | 8/5/20 |
GRAM to manufacture and distribute vaccines or therapeutics related to the COVID-19 to U.S. DOD | Grand River Aseptic Manufacturing | U.S. Department of Defense | Payment unspecified | 8/6/20 |
HMS to study and develop therapies against emergent viral infections caused by coronaviruses and by viruses lead to hemorrhagic fever | Harvard Medical School | Abbvie Inc. | $30.00 | 8/25/20 |
Gene Techno Science and Hokkaido university to develop a stem cell therapy for non-union fractures | Hokkaido University | Gene Techno Science Co. Ltd. | Payment unspecified | 8/20/20 |
Hong Kong Polytechnic University and Macau University of Science and Technology to develop recombinant RBD vaccine against COVID-19 | Hong Kong Polytechnic University | Macau University of Science and Technology | Payment unspecified | 8/3/20 |
Institut Pasteur Korea to develop Daewoong’s Foistar against COVID-19 | Institut Pasteur Korea | Daewoong Pharmaceutical Co. Ltd. | Payment unspecified | 8/20/20 |
Covidx to develop Institute for Tropical Medicine Tubingen's Oracov against COVID-19 | Institute for Tropical Medicine Tubingen | Covidx | Payment unspecified | 8/7/20 |
Carlos Slim to produce Astrazeneca's COVID-19 vaccine for phase III clinical trials and regulatory approvals | Instituto Carlos Slim de la Salud | Astrazeneca plc | Payment unspecified | 8/14/20 |
Janssen to supply Ad26COVS to Canadian Government | Janssen Inc. | Canadian Government | Payment unspecified | 8/31/20 |
Janssen received more than $1B to produce 100M doses of Ad26.COV2.S from U.S. Government | Janssen Pharmaceuticals Inc. | U.S. Government | $1,000.00 | 8/12/20 |
Johnson & Johnson to supply Ad26.COV2-S vaccine against COVID-19 to Government of Canada | Johnson & Johnson | Canadian Government | Payment unspecified | 8/31/20 |
pCPA to sign letter of intent to commercialize Kaleo's Allerject auto-injector for the serious allergic reactions in Canada | Kaleo Inc. | Pan-Canadian Pharmaceutical Alliance | Payment unspecified | 8/10/20 |
Novo Nordisk and Karolinska Institutet to develop cell therapy treatments for dry age-related macular degeneration | Karolinska Institutet | Novo Nordisk A/S | $4.96 | 8/24/20 |
King's College London to study the immunological effects of Elstar's T-cell engager antibodies against cancer and other diseases | King's College London | Elstar Therapeutics | Payment unspecified | 8/5/20 |
MGCC and Natera to conduct phase II clinical trial of Ribociclib in ER-positive early stage breast cancer | Massachusetts General Hospital Cancer Center | Natera Inc. | Payment unspecified | 8/27/20 |
Mayo Clinic to perform research on Plakous Therapeutics' Protego-PD for necrotizing enterocolitis | Mayo Clinic Foundation | Plakous Therapeutics Inc. | Payment unspecified | 8/25/20 |
Diaprost to license intellectual property related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer | Memorial Sloan-Kettering Cancer Center | Diaprost AB | Payment unspecified | 8/25/20 |
Seneca to use Memorial Sloan Kettering Cancer Center’s TEM8 intellectual property rights against cancer | Memorial Sloan-Kettering Cancer Center | Seneca Therapeutics Inc. | Payment unspecified | 8/31/20 |
Gentibio to use Migal’s regulatory T-cell engineering technologies to develop Engtregs for autoimmune and inflammatory diseases | Migal – Galilee Research Institute | Gentibio Inc. | Payment unspecified | 8/5/20 |
Moderna Therapeutics to supply mRNA-1273 for COVID-19 infection to U.S. Department of Defense | Moderna Inc. | U.S. Department of Defense | $1,525.00 | 8/11/20 |
Moderna to supply 4.5 million doses of mRNA-1273 vaccine against COVID-19 to Swiss government | Moderna Inc. | Swiss government | Payment unspecified | 8/7/20 |
Moderna to supply mRNA-1273 vaccine against COVID-19 to Government of Canada | Moderna Therapeutics | Canadian Government | Payment unspecified | 8/31/20 |
Moderna to supply mRNA-1273 to Japanese Ministry of Health, Labor and Welfare against Covid-19 in Japan | Moderna Therapeutics | Japanese Ministry of Health, Labor and Welfare | Payment unspecified | 8/28/20 |
Molecular Partners to supply doses of MP-0420 to Swiss Federal Office for the treatment of COVID-19 infection | Molecular Partners AG | Swiss Federal Office of Public Health | Payment unspecified | 8/11/20 |
Mount Sinai School to conduct clinical study of Xortx' XRx-101 for acute kidney injury and hyperuricemia associated with COVID-19 | Mount Sinai School of Medicine | Xortx Therapeutics Inc. | Payment unspecified | 8/4/20 |
NIAID to evaluate the efficacy of Pharmabcine's PMC-403 to treat systemic capillary leak syndrome | National Institute of Allergy and Infectious Diseases | Pharmabcine | Payment unspecified | 8/18/20 |
JN Nova Pharma and NRC to develop a therapeutic platform for severe pathologies associated with COVID-19 | National Research Council of Canada | JN Nova Pharma Inc. | Payment unspecified | 8/14/20 |
Vyripharm to sign memorandum of understanding with NYMU to develop bio-distribution and targeting profile of VYR-206 for monitoring treatment outcomes of neurological disorders | National Yang Ming University | Vyripharm Biopharmaceuticals | Payment unspecified | 8/5/20 |
U.K. Government to purchase doses of Novavax's NVX-CoV2373 for the treatment of COVID-19 infection | Novavax Inc. | U.K. Government | Payment unspecified | 8/14/20 |
Novavax to supply NVX-CoV2373 COVID vaccine to the Government of Canada | Novavax Inc. | Canadian Government | Payment unspecified | 8/31/20 |
Carisma to develop and commercialize NYU Langone's Vpx Lentiviral Vector worldwide for various indications | NYU Langone Health | Carisma Therapeutics | Payment unspecified | 8/25/20 |
Penn State Cancer Institute and Caris Life Sciences to advance precision medicine in oncology | Penn State Cancer Institute | Caris Life Sciences | Payment unspecified | 8/25/20 |
Prescient Therapeutics and Peter MacCallum Cancer Centre to develop CAR-T cancer therapy | Peter MacCallum Cancer Centre | Prescient Therapeutics Ltd. | Payment unspecified | 8/14/20 |
Abbvie, Amgen and Takeda to join Quantum Leap Healthcare's I-SPY clinical study of cenicriviroc, Otezla and Firazyr against COVID-19 | Quantumleap Healthcare | Abbvie Inc. | Payment unspecified | 8/3/20 |
TaiMed to use Columbia's COVID-19 neutralizing antibody against COVID-19 worldwide | Taimed Biologics Inc. | Columbia University | Payment unspecified | 8/25/20 |
T-Cure expanded its agreement with National Heart Lung and Blood Institute to advance HERV-E targeting TCR therapy for renal cell cancer | T-Cure Bioscience Inc. | National Heart Lung and Blood Institute | Payment unspecified | 8/4/20 |
Champalimaud to perform research on Immodulon's IMM-101 against advanced epithelial cancers | The Champalimaud Foundation | Immodulon Therapeutics Ltd. | Payment unspecified | 8/3/20 |
FAST and Lixte Biotechnology to support preclinical study of LB-100 for Angelman Syndrome | The Foundation for Angelman Syndrome Therapeutics | Lixte Biotechnology Holdings Inc. | Payment unspecified | 8/18/20 |
The Ivy Brain Tumor Center to develop Vivace Therapeutics' TEAD inhibitor, VT-01 for glioblastoma and meningioma | The Ivy Brain Tumor Center | Vivace Therapeutics Inc. | Payment unspecified | 8/26/20 |
Thomas Jefferson University to evaluate Tevogen's antigen-specific T cell technology against COVID-19 and influenza A infections | Thomas Jefferson University | Tevogen Bio | Payment unspecified | 8/10/20 |
Mammoth Biosciences licensed from the University of California at Berkeley a new CRISPR protein family, Cas?, for research, development and commercialization in all fields | University of California at Berkeley | Mammoth Biosciences Inc. | Payment unspecified | 8/12/20 |
University of Florida and Sarepta to discover and develop therapies for rare genetic diseases | University of Florida | Sarepta Therapeutics Inc. | Payment unspecified | 8/11/20 |
AIkido Pharma to support the research and develop University of Kentucky's G4-1 for the treatment of solid tumor with an option | University of Kentucky | AIkido Pharma Inc. | Payment unspecified | 8/18/20 |
University of Manitoba and Theralase to develop vaccine against COVID-19 | University of Manitoba | Theralase Technologies Inc. | Payment unspecified | 8/19/20 |
Sernova to commercialize University of Miami's cell immune protection technologies for type 1 diabetes and other chronic diseases worldwide | University of Miami | Sernova Corp. | Payment unspecified | 8/4/20 |
University of Pennsylvania to advance the Hemogenyx' HEMO-CAR-T into clinical for acute myeloid leukemia | University of Pennsylvania | Hemogenyx Pharmaceuticals Ltd. | Payment unspecified | 8/11/20 |
University of Texas to conduct research study of Geovax's vaccine against Sudan Ebolavirus and Marburg Virus infection | University of Texas Medical Branch at Galveston | Geovax Labs Inc. | Payment unspecified | 8/13/20 |
Respirerx Pharmaceuticals exercised an option agreement with the UWM Research Foundation for a patent license covering GABAA receptor neuromodulator intellectual property, including U.S. patents 9,006,233, 9,597,342 and 10,259,815 and a Canadian patent application | UWM Research Foundation Inc. | Respirerx Pharmaceuticals Inc. | Payment unspecified | 8/4/20 |
Virpax to enter CRADA with NCATS to conduct research on NES-100 for acute and chronic non-cancer pain | Virpax Pharmaceuticals | National Center For Advancing Translational Sciences | Payment unspecified | 8/31/20 |
Wockhardt to manufacture COVID-19 vaccine, including AZD-1222 to U.K. Government | Wockhardt Ltd. | U.K. Government | Payment unspecified | 8/3/20 |
Hainan to use intellectual property rights to develop Zhejiang's PLAT-001 against cancer worlwide | Zhejiang University | Hainan Poly Pharm Co. Ltd. | $2.82 | 8/28/20 |
Acelrx Pharmaceuticals received an initial contract from the U.S. Army for the purchase of Dsuvia (sufentanil sublingual tablet) | Acelrx Pharmaceuticals Inc. | U.S. Army | $3.60 | 9/22/20 |
Ajinomoto Bio-Pharma Services to manufacture DNDi’s CpG-D35 for cutaneous leishmaniasis infections | Ajinomoto Bio-Pharma Services | Drugs for Neglected Diseases initiative | Payment unspecified | 9/29/20 |
Arizona to conduct phase I study of Covistat's nafamostat for the treatment of COVID-19 infection | Arizona Research Center | Covistat | Payment unspecified | 9/28/20 |
Astrazeneca to supply AZD-1222 vaccine to Government of Canada for COVID-19 prevention | Astrazeneca plc | Canadian Government | Payment unspecified | 9/25/20 |
Biontech to supply European Commission with BNT-162, mRNA-based vaccine candidate against COVID-19 | Biontech SE | European Commission | Payment unspecified | 9/10/20 |
Bostongene and Brigham and Women’s Hospital to analyze whole transcriptome sequencing datasets generated from tumor and blood samples from patients with recurrent glioblastoma and who are treated with an oncolytic virus | Brigham and Women’s Hospital | Bostongene Corp. | Payment unspecified | 9/15/20 |
Charcot-Marie-Tooth Association and Pharnext to research on CMT1A biomarkers to support the phase III trial of PXT-3003 | Charcot-Marie-Tooth Association | Pharnext SA | Payment unspecified | 9/11/20 |
SpringWorks and COG to evaluate nirogacestat in a phase II trial for the progressive, surgically unresectable desmoid tumors in children and adolescents | Children's Oncology Group | SpringWorks Therapeutics Inc. | Payment unspecified | 9/16/20 |
Chimeric to use patents related to City of Hope’s CLTX-CAR T cell therapy against cancer worldwide | City of Hope | Chimeric Therapeutics Ltd. | Payment unspecified | 9/21/20 |
Revision Therapeutics to develop and commercialize Cornell's technology against stargardt disease | Cornell University | Revision Therapeutics Inc. | Payment unspecified | 9/1/20 |
Applied Biology and Corpometria Institute to study the role of proxalutamide in COVID-19 patients | Corpometria Institute | Applied Biology Inc. | Payment unspecified | 9/22/20 |
CSL to supply UQ's protein subunit vaccine against COVID-19 to Australian Government | CSL Ltd. | Australian Government | Payment unspecified | 9/7/20 |
Kazia Therapeutics and Dana-Farber Cancer Institute to assess its kinase inhibitor, paxalisib in primary central nervous system lymphoma | Dana-Farber Cancer Institute | Kazia Therapeutics Ltd. | Payment unspecified | 9/22/20 |
Dr. Reddy’s and RDIF to conduct clinical trials of the Sputnik V vaccine and to distribute 100 million doses in India | Dr Reddy's Laboratories Ltd. | Russian Direct Investment Fund | Payment unspecified | 9/30/20 |
RDIF to supply 100M doses of Sputnik V COVID-19 vaccine in India to Dr. Reddy's Laboratories | Dr. Reddy's Laboratories Ltd. | Russian Direct Investment Fund | Payment unspecified | 9/16/20 |
Duke University to use the MPTP-induced Parkinson's disease mouse model to test Seelos' SLS-004 | Duke University | Seelos Therapeutics Inc. | Payment unspecified | 9/23/20 |
Duke University and Cura Foundation to support the clinical trial of hCT-MSC to treat Multisystem Inflammatory Syndrome in children | Duke University | Cura Foundation | Payment unspecified | 9/16/20 |
Elevation and U.S. Oncology will collaborate on a patient enrollment program in the registration-enabling phase II Crestone study for patients with solid tumors of any origin that have an NRG1 gene fusion | Elevation Oncology Inc. | U.S. Oncology Research | Payment unspecified | 9/30/20 |
Evotec and Bioaster to develop therapeutics against infectious diseases and antimicrobial resistance | Evotec SE | Bioaster | Payment unspecified | 9/14/20 |
Fred Hutchinson Cancer Research Center to evaluate Springworks' Nirogacestat as a BCMA modulator against multiple myeloma | Fred Hutchinson Cancer Research Center | Springworks Therapeutics Inc. | Payment unspecified | 9/18/20 |
AMED to award a contract to Fujita to initiate a phase I/II clinical trial of EXG-5003 against COVID-19 | Fujita Health University | Japan Agency for Medical Research and Development | Payment unspecified | 9/1/20 |
Dutch Amarna Therapeutics and FPS to study the efficacy of SVec gene delivery vector platform technology in DM1 and MS | Fundacion Publica Andaluza Progreso y Salud | Amarna Therapeutics BV | $0.66 | 9/25/20 |
Cullinan Oncology, the German Cancer Research Center and the Eberhard Karls University of Tubingen formed Cullinan Florentine to develop a FLT3 x CD3 bispecific antibody for treating patients with acute myeloid leukemia | German Cancer Research Center | Cullinan Oncology LLC | Payment unspecified | 9/15/20 |
GCRBC to supply universal donor starting material for the manufacture of Kiadis' off -the-shelf K-NK Natural Killer (NK) cell therapies in the US | Gulf Coast Regional Blood Center | Kiadis Pharma BV | Payment unspecified | 9/28/20 |
Moffitt Cancer Center to perform research on Elicio’s AMP-CD19 in combination with CD19 CAR T cells against B-cell malignancies | H Lee Moffitt Cancer Center and Research Institute | Elicio Therapeutics Inc. | Payment unspecified | 9/17/20 |
Canbridge Pharmaceuticals expanded its gene therapy collaboration with the Horae Gene Therapy Center at the University of Massachusetts Medical School for the development of customized adeno-associated virus vectors against neuromuscular diseases | Horae Gene Therapy Center at the University of Massachusetts Medical School | Canbridge Pharmaceuticals Inc. | Payment unspecified | 9/8/20 |
HSG to conduct a PROOF-HD study for Prilenia Therapeutics’ Pridopidine against Huntington’s Disease | Huntington Study Group | Prilenia Therapeutics Development Ltd. | Payment unspecified | 9/17/20 |
Imperial College London to use CN Bio's 3D Liver-on-Chip technology to investigate the mechanism of alcoholic hepatitis | Imperial College London | CN Bio Innovations Ltd. | Payment unspecified | 9/9/20 |
IPK to conduct a phase II clinical study of Chong Kun Dang's nafamostat against COVID-19 | Institut Pasteur Korea | Chong Kun Dang Pharmaceutical Corp. | Payment unspecified | 9/3/20 |
JLABS and BARDA to develop 7HP-349 for the treatment of COVID-19 infection | Johnson & Johnson Innovation, JLABS | U.S. Department of Health and Human Services | Payment unspecified | 9/5/20 |
Kiadis to use AWRI's IP related to NK cells for treatment of microbial infections | Kiadis Pharma BV | Abigail Wexner Research Institute | Payment unspecified | 9/14/20 |
KYAN Therapeutics to license small Molecule HDAC Inhibitors for AI based cancer drug ddevelopment exclusively to Georgetown University | Kyan Therapeutics Inc. | Georgetown University | Payment unspecified | 9/24/20 |
Landsteiner to distribute Gamalei 's Sputnik V against COVID-19 in Mexico | Landsteiner Scientific Sa De Cv | Gamalei Institute of Epidemiology and Microbiology | Payment unspecified | 9/10/20 |
LUMC to conduct research on Pharmaust's monepantel and monepantel sulfone drugs for COVID-19 | Leiden University Medical Center | Pharmaust Ltd. | Payment unspecified | 9/24/20 |
Sorrento to use Mayo Clinic's antibody-drug-nanoparticle albumin-bound immune complexes for the treatment of various solid and liquid tumors | Mayo Clinic Foundation | Sorrento Therapeutics Inc. | $12.70 | 9/8/20 |
McGill University Health Centre to conduct phase II clinical trial on Theralase's TLD-1433 for bladder cancer | McGill University Health Center | Theralase Technologies Inc. | Payment unspecified | 9/24/20 |
MD Anderson to conduct study to evaluate Xencor's XmAb drugs against cancers | MD Anderson Cancer Center | Xencor Inc. | Payment unspecified | 9/3/20 |
MD Anderson to evaluate Astex's Inqovi in combination with other therapies for the treatment of leukemia | MD Anderson Cancer Center | Astex Pharmaceuticals Inc. | Payment unspecified | 9/8/20 |
MD Anderson and Taiho Pharmaceutical to accelerate development of therapies for brain metastasis and other indications | MD Anderson Cancer Center | Taiho Pharmaceutical Co. Ltd. | Payment unspecified | 9/24/20 |
MSK to develop Atara’s ATA-2271 for advanced mesothelioma | Memorial Sloan-Kettering Cancer Center | Atara Biotherapeutics Inc. | Payment unspecified | 9/8/20 |
Fiocruz and Murdoch Children’s Research Institute to test BCG vaccine against COVID-19 | Murdoch Childrens Research Institute | Fundacao Oswaldo Cruz (Fiocruz) | Payment unspecified | 9/24/20 |
MCRI to evaluate Recce Pharmaceuticals' RECCE-435 for the treatment of H.pylori infections | Murdoch Childrens Research Institute | Recce Pharmaceuticals Ltd. | Payment unspecified | 9/30/20 |
Navrogen to commercialize NCI's mesothelin-targeting agents against Immuno-suppressed cancers | National Cancer Institute | Navrogen Inc. | Payment unspecified | 9/29/20 |
NIH to conduct phase II study of Calcilytix's encaleret for the treatment of ADH1 | National Institutes of Health | Calcilytix Therapeutics | Payment unspecified | 9/21/20 |
Pharco to supply RDIF's Sputnik V vaccine against COVDI-19 in Egypt | Pharco Pharmaceuticals Inc. | Russian Direct Investment Fund | Payment unspecified | 9/30/20 |
Locate Bio to develop RCSI's multiple orthobiologics assets including collagen-based delivery technologies to treat infection and regeneration of cartilage tissues | RCSI University of Medicine and Health Sciences | Locate Therapeutics Ltd. | Payment unspecified | 9/21/20 |
NHLBI to conduct phase II study to evaluate the safety of Rigel's Fostamatinib for the treatment of COVID-19 infection | Rigel Pharmaceuticals Inc. | National Institutes of Health | Payment unspecified | 9/17/20 |
Bridge Medicines and The Rockefeller University to further develop a series of small molecule inhibitor Factor XII against hereditary angioedema | Rockefeller University | Bridge Medicines LLC | Payment unspecified | 9/21/20 |
RDIF to supply Sputnik V to Brazil’s Bahia State for COVID-19 infection | Russian Direct Investment Fund | BAHIA SECRETARIA DE SAUDE DO ESTADO | Payment unspecified | 9/11/20 |
RDIF to supply Sputnik V vaccine to Trinity Pharmaceuticals in Nepal | Russian Direct Investment Fund | Trinity Pharmaceutical | Payment unspecified | 9/29/20 |
RDIF to supply Sputnik V vaccine to Laxisam in Uzbekistan for COVID-19 | Russian Direct Investment Fund | Laxisam Pharmaceuticals | Payment unspecified | 9/25/20 |
Sanford Burnham Prebys Medical Discovery Institute and Fondazione Santa Lucia IRCCS to perform research on HDACi for Duchenne muscular dystrophy | Sanford-Burnham Medical Research Institute | Fondazione Santa Lucia IRCCS | Payment unspecified | 9/15/20 |
Sanofi and Glaxosmithkline to supply up to 72M doses of an adjuvanted COVID-19 vaccine to Canadian government | Sanofi SA | Canadian government | Payment unspecified | 9/22/20 |
Sanofi to supply COVID-19 vaccine to European Union | Sanofi SA | The European Union | $356.63 | 9/18/20 |
Saint Louis University to conduct phase I trials of a single nasal dose of Washington University School of Medicine in St. Louis' VSV-SARS-CoV-2 for COVID-19 infection | St Louis University | Washington University School of Medicine, US | Payment unspecified | 9/23/20 |
Kentucky Organ Donor Affiliates to advance the preclinical study of Talaris’ allogeneic cell therapy against kidney transplantation | Talaris Therapeutics Inc. | Kentucky Organ Donor Affiliates | Payment unspecified | 9/14/20 |
LLS to conduct clinical trials of AstraZeneca's acalabrutinib for blood cancer patients with COVID-19 infection | The Leukemia & Lymphoma Society | Astrazeneca plc | Payment unspecified | 9/9/20 |
Mindmed and the University Hospital Basel’s Liechti Lab collaborate to advance the understanding of altered states of consciousness induced by psilocybin and LSD. | University Hospital Basel | Mindmed Inc. | Payment unspecified | 9/24/20 |
Lodo to acquire IP related rights of UCR's TIR-199 for the treatment of solid tumors and cancer | University of California Riverside | Lodo Therapeutics Corp. | Payment unspecified | 9/3/20 |
University of Edinburgh to conduct CAReS study for Artelo Bioscience’s ART27.13 in phase I/II trial against cancer anorexia and weight loss | University of Edinburgh | Artelo Biosciences Inc. | Payment unspecified | 9/29/20 |
University of Malaya to conduct clinical trial for BiocurePharm's CAR T therapy against acute lymphocyte leukemia | University of Malaya | Biocurepharm Co. Ltd. | Payment unspecified | 9/10/20 |
LUCA and University of Oxford to develop therapies against intrauterine growth restriction using drug delivery technology | University of Oxford | Luca Science Inc. | Payment unspecified | 9/29/20 |
University of Liverpool and University of Oxford to research on vaccine development for coronavirus infection | University of Oxford | The University of Liverpool | Payment unspecified | 9/14/20 |
University of Oxford to conduct RECOVERY trial to evaluate Regeneron Pharmaceutical’s REGN- CoV2 in COVID-19 patients | University of Oxford | Regeneron Pharmaceuticals Inc. | Payment unspecified | 9/14/20 |
Alaxia and the University of Padova’s Department of Molecular Medicine to test in vitro the virucidal effect of ALX-009 against SARS-CoV-2 | University of Padova | Alaxia SAS | Payment unspecified | 9/21/20 |
University of Pittsburgh and Astellas to evaluate and optimize AAV based gene therapy clinical candidates for the treatment of dry AMD | University of Pittsburgh | Astellas Pharma Inc. | Payment unspecified | 9/24/20 |
Monopar and Northstar Medical Radioisotopes formed a collaboration with the University of Texas Health Science Center at Tyler (UTHSCT) and its Texas Lung Injury Institute to evaluate uPRIT candidates for severe COVID-19 infection | University of Texas Health Science Center at Tyler | Monopar Therapeutics Inc. | Payment unspecified | 9/9/20 |
Dexcom agreed with University of Virginia to advance its development and research efforts on continuous glucose monitoring-based solutions | University of Virginia | Dexcom Inc. | Payment unspecified | 9/24/20 |
Valneva to supply VLA-2001 to U.K. government against COVID-19 infection | Valneva SE | U.K. Government | $1,700.00 | 9/14/20 |
Valneva to supply its Japanese encephalitis vaccine, Ixiaro to U.S. Department of Defense | Valneva SE | U.S. Department of Defense | $166.00 | 9/9/20 |
Vectura to manufacture Monash University's inhaled oxytocin against postpartum haemorrhage in childbirth | Vectura Group plc | Monash University | Payment unspecified | 9/14/20 |
Promis and Vido-Intervac to develop multivalent vaccine for Alzheimer’s disease | Vido-Intervac | Promis Neurosciences Inc. | Payment unspecified | 9/22/20 |
Waisman Biomanufacturing to maufacture Gigagen's GIGA-2050 against COVID-19 | Waisman Clinical Biomanufacturing Facility | Gigagen Inc. | Payment unspecified | 9/9/20 |
Precision Virologics to obtain option rights of Washington University's intranasal COVID-19 vaccine in USA, Europe, and Japan | Washington University School of Medicine | Precision Virologics Inc. | Payment unspecified | 9/23/20 |
Bharat Biotech to obtain rights of Washington University's intranasal COVID-19 vaccine in all markets except USA, Europe, and Japan | Washington University School of Medicine | Bharat Biotech International Ltd | Payment unspecified | 9/23/20 |
University of Louisville to conduct phase I/II clinical trial of Actinium's Actimab-A venetoclax combination against AML | Actinium Pharmaceuticals Inc | University of Louisville | Payment unspecified | 10/6/20 |
Amyris signed collaboration and license agreements to advance a ribonucleic acid vaccine platform, including accelerating development of a COVID-19 vaccine | Amyris Inc. | Infectious Disease Research Institute | Payment unspecified | 10/22/20 |
Argenx entered a nonexclusive research agreement to use Clayton’s DHS mutations for extending the serum half-life of therapeutic antibodies | Argenx SE | Clayton Foundation for Research | Payment unspecified | 10/6/20 |
Astrazeneca received about $486M from the U.S. government to support the development and supply of a long-acting antibody combination, AZD-7442, under evaluation for the prevention and treatment of COVID-19 | Astrazeneca plc | U.S. government | $486 | 10/12/20 |
ATCC received an indefinite delivery/indefinite quantity contract award to join BARDA's Clinical Studies Network and provide a biological specimen and investigational product storage facility with centralized services | ATCC | U.S. Biomedical Advanced Research and Development Authority | $250.00 | 10/6/20 |
Auravax entered an exclusive license option agreement covering the intellectual property for a novel intranasal vaccine technology; the company is developing a differentiated platform of vaccines against various respiratory viruses, including COVID-19 | Auravax Therapeutics Inc. | University of Houston | Payment unspecified | 10/12/20 |
Biontech to supply BNT-162b2 to New Zealand government for COVID-19 infection | Biontech SE | New Zealand Government | Payment unspecified | 10/12/20 |
BIRAC to support Reddy's Sputnik V vaccine clinical trials for COVID-19 in India | Biotechnology Industry Research Assistance Council | Dr. Reddy's Laboratories Ltd. | Payment unspecified | 10/29/20 |
Bridge Medicines and The Rockefeller University to develop anti-inflammatory drug | Bridge Medicines | Rockefeller University | Payment unspecified | 10/19/20 |
Celiac Disease Foundation to conduct phase IIb study for Provention Bio's PRV-015 against celiac disease | Celiac Disease Foundation | Provention Bio Inc. | Payment unspecified | 10/7/20 |
Celltrion to supply Herzuma and Truxima biosimilars against cancer to Government of Brazil | Celltrion Healthcare Co. Ltd. | Brazilian Government | Payment unspecified | 10/13/20 |
CHDR to conduct phase I clinical trial on Entheon's DMT product for addiction | Centre for Human Drug Research | Entheon Biomedical Corp. | Payment unspecified | 10/7/20 |
Cerus was awarded a five-year, $11.1M contract from the FDA for the development of next-generation compounds to optimize pathogen reduction treatment of whole blood to reduce the risk of transfusion-transmitted infections | Cerus Corp. | FDA | $11.10 | 10/13/20 |
FDA to award Cerus contract to develop pathogen reduction (PR) treatment technology for transfusion-transmitted infections | Cerus Corp. | Food and Drug Administration | $11.10 | 10/13/20 |
Neximmune and City of Hope to investigate on AIM technology based T-cell therapy approaches to treat AML | City of Hope | Neximmune Inc. | Payment unspecified | 10/27/20 |
Argenx to use Clayton's antibody engineering technologies including DHS mutations to extend the serum half-life of therapeutic antibodies | Clayton Foundation For Research | Argenx NV | Payment unspecified | 10/6/20 |
Columbia University to evaluate Biolinerx's Motixafortide in combination with Libtayo and chemotherapy as a first-line metastatic PDAC | Columbia University | Biolinerx Ltd. | Payment unspecified | 10/29/20 |
Eisai's joint research agreement concerns the development of therapeutics to prevent the aggravation of COVID-19; a Toll-like receptor 4 antagonist, eritoran, discovered by Eisai, and an anti-fractalkine antibody, E-6011, discovered by Eisai’s research subsidiary Kan, will be evaluated | Eisai Co. Ltd. | Kan Research Institute, National Center for Global Health and Medicine, Nagasaki University and Yokohama City University in Japan | Payment unspecified | 10/6/20 |
Eli Lilly to supply therapeutic antibodies to BMGF for treatment of COVID-19 in low- and middle-income countries | Eli Lilly and Co. | Bill & Melinda Gates Foundation | Payment unspecified | 10/8/20 |
Eli Lilly to supply bamlanivimab to U.S. Government for the treatment of COVID-19 infection | Eli Lilly and Co. | U.S. Government | $1,187.50 | 10/28/20 |
FDA to sign a CRADA for toxicology testing using Emulate's Organs-on-Chips technology | Emulate Inc. | Food and Drug Administration | Payment unspecified | 10/29/20 |
Entos is receiving advisory services and funding to support development of domestic COVID-19 vaccine candidates, including its preclinical Fusogenix DNA vaccine | Entos Pharmaceuticals Inc. | National Research Council of Canada Industrial Research Assistance Program | $3.80 | 10/23/20 |
Entos is working with Applied in enhancing its Alberta-based vaccine production capacity, following a greater presence in Edmonton with the rapid development of the Fusogenix DNA vaccine candidates for COVID-19 | Entos Pharmaceuticals Inc. | Applied Pharmaceutical Innovation | Payment unspecified | 10/28/20 |
Fiona Stanley to conduct phase I/II trial to evaluate the safety and efficacy of Recce's RECCE-327 on patients with infected burn wounds | Fiona Stanley Hospital | Recce Pharmaceuticals Ltd. | Payment unspecified | 10/16/20 |
Matrix and Fred Hutchinson to research on COVID-19 vaccines | Fred Hutchinson Cancer Research Center | Matrix Medical LLC | Payment unspecified | 10/1/20 |
Lantern Pharma to further collaborate with Georgetown University for LP-184 drug candidate currently in preclinical development for solid tumors | Georgetown University | Lantern Pharma Inc. | Payment unspecified | 10/5/20 |
Gilead to supply it's remdesivir to European Commission for the treatment of COVID-19 | Gilead Sciences Inc. | European Commission | Payment unspecified | 10/7/20 |
Hackensack University Medical Center to initiate phase I clinical trial of Imugene’s PD1-Vaxx against non-small-cell lung carcinoma in the U.S. | Hackensack University Medical Center | Imugene Ltd. | Payment unspecified | 11/2/20 |
Citranvi Biosciences to use HJF’s herpes virus vaccine technology to develop vaccine against cytomegalovirus and Epstein-Barr virus infections | Henry M Jackson Foundation for the Advancement of Military Medicine | Citranvi Biosciences LLC | Payment unspecified | 10/20/20 |
Hospital do Coracao to conduct phase II clinical study for Ionis Pharmaceuticals’ IONIS-PKK-LRx in COVID-19 patients | Hospital do Coracao | Ionis Pharmaceuticals Inc. | Payment unspecified | 10/15/20 |
Indapta and MMRF partnered to support the universal G-NK cell therapy to treat patients with multiple myeloma | Indapta Therapeutics Inc. | Multiple Myeloma Research Foundation | Payment unspecified | 10/28/20 |
Cytovia and Inserm to develop natural killer engager bispecific antibodies and induced pluripotent stem cell chimeric antigen receptor NK cell therapy targeting CD38 for multiple myeloma | Inserm | Cytovia Therapeutics | Payment unspecified | 10/8/20 |
Merck to develop IAVI's monoclonal antibody for COVID-19 worldwide | International AIDS Vaccine Initiative | Merck & Co. Inc. | Payment unspecified | 10/22/20 |
J&J to supply COVID-19 vaccine candidate to European Commission | Johnson & Johnson | European Commission | Payment unspecified | 10/8/20 |
Kamada to supply plasma-derived anti-SARS-CoV-2 IgG to Israeli MoH | Kamada Ltd. | Ministry of Health, Israel | Payment unspecified | 10/19/20 |
Kamada will manufacture an investigational COVID-19 plasma-derived immunoglobulin therapy under a supply agreement with Israeli health authorities | Kamada Ltd. | Kedrion Biopharma SpA | Payment unspecified | 10/22/20 |
Kiadis entered a collaboration in which GCRBC will supply universal donor starting material for the manufacture of Kiadis' off-the-shelf K-NK natural killer cell therapies in the U.S. | Kiadis Pharma NV | Gulf Coast Regional Blood Center | Payment unspecified | 10/26/20 |
MD Anderson Cancer center to evaluate Allogene Therapeutics' multiple preclinical and clinical AlloCAR T candidates against hematologic and solid tumors | MD Anderson Cancer Center | Allogene Therapeutics Inc. | Payment unspecified | 10/15/20 |
Medicago reached an agreement to supply the Canadian government with up to 76M doses of its COVID-19 vaccine and to construct its Quebec City manufacturing facility | Medicago Inc. | Canadian government | $131.60 | 10/23/20 |
Moderna to supply mRNA-1273 vaccine against COVID-19 to Ministry of Public Health of Qatar | Moderna Inc. | Ministry of Public Health of Qatar | Payment unspecified | 10/26/20 |
Moderna received a commitment of up to $56M to fund development of a mobile manufacturing protype to rapidly produce vaccines and therapeutics | Moderna Inc. | U.S. Defense Advanced Research Projects Agency | $56.00 | 10/8/20 |
Lactiga and Mount Sinai medical center to advance preclinical research into LCTG-001 for treatment of COVID-19 patients | Mount Sinai Medical Center | Lactiga Inc. | Payment unspecified | 10/14/20 |
Connectyx to use IP rights of NCI's antibody-drug conjugate to treat brain cancer worldwide with an option | National Cancer Institute | Connectyx | Payment unspecified | 10/16/20 |
NCCN to evaluate Puma's Neratinib for the treatment of various cancers | National Comprehensive Cancer Network | Puma Biotechnology Inc. | $2.00 | 10/15/20 |
NIAID to conduct a clinical study to evaluate the safety, tolerability, and efficacy of Emergent’s COVID-HIG in phase III clinical trial against COVID-19 | National Institute of Allergy and Infectious Diseases | Emergent Biosolutions Inc. | Payment unspecified | 10/8/20 |
GeoVax to use NIAID's patent and biological materials to develop MVA-VLP vaccine for COVID-19 worldwide | National Institute of Allergy and Infectious Diseases | Geovax Labs Inc. | Payment unspecified | 10/22/20 |
Novocure signed an alliance for preclinical and clinical development projects studying Novocure’s Tumor Treating Fields (TTFs), electric fields that disrupt cancer cell division | Novocure Inc. | NYU Grossman School of Medicine's radiation oncology department | Payment unspecified | 10/29/20 |
NYU Langone Health to conduct proof of concept study for Caladrius Biosciences’ CLBS-119 in COVID-19 | NYU Langone Health | Caladrius Biosciences Inc. | Payment unspecified | 10/8/20 |
NYU Langone Health and Ixico to develop imaging biomarkers for FDA approved sirolimus trial for MSA | NYU Langone Health | Ixico plc | Payment unspecified | 10/16/20 |
Oblique and its collaborators were granted SEK5M (US$563,859) by Vinnova, the Swedish government’s innovation agency, to develop neutralizing antibodies against SARS-CoV-2 and to use its Abiprot platform to develop antibodies swiftly against future pandemics | Oblique Therapeutics AB | Sahlgrenska University Hospital and Karolinska Institutet | $0.56 | 10/8/20 |
The Ohio State University and Biovaxys Technology to conduct research on SARS-CoV-2 vaccine candidate, BVX-0320 | Ohio State University | Biovaxys Technology Corp. | Payment unspecified | 10/26/20 |
OHSU to transfer human material and data to Oxford Biodynamics to advance EpiSwitch program for COVID-19 infection | Oregon Health Sciences University | Oxford Biodynamics Ltd | Payment unspecified | 10/28/20 |
Organicell inked an agreement for clinical research projects investigating use of lead therapeutic, Zofin, to treat heart failure with preserved ejection fraction | Organicell Regenerative Medicine Inc. | Regenerative Care Network | Payment unspecified | 10/20/20 |
Panacea, a startup company formed by BGN Technology, the technology transfer company of Ben-Gurion University licensed a machine learning platform | Panacea | Ben-Gurion University | Payment unspecified | 10/22/20 |
AllStripes and Perelman School to conduct research and participate in development of gene therapies for Lesch-Nyhan disease | Perelman School of Medicine | Allstripes | Payment unspecified | 10/26/20 |
NCI to conduct phase I clinical trial for Plus Therapeutics’ Rhenium NanoLiposomes in GBM | Plus Therapeutics Inc. | National Cancer Institute | Payment unspecified | 10/1/20 |
Precision Nanosystems received a commitment from the Canadian government to develop a COVID-19 vaccine | Precision Nanosystems Inc. | Canadian government | $13.80 | 10/23/20 |
Qualigen entered an amended sponsored research agreement to study the cancer drug candidate, AS1411-GNP | Qualigen Therapeutics Inc. | University of Louisville | Payment unspecified | 10/1/20 |
Sanofi to sign statement of intent with Gavi to supply 200 million doses of COVID-19 vaccine | Sanofi Pasteur | Global Alliance for Vaccines and Immunization | Payment unspecified | 10/28/20 |
SITraN to validate Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases | Sheffield Institute for Translational Neuroscience | Quell Therapeutics Ltd. | Payment unspecified | 10/26/20 |
Silo Pharma executed an option agreement to use central nervous system-homing peptides in vivo as a potential treatment of multiple sclerosis and other neuroinflammatory pathology | Silo Pharma Inc. | University of Maryland | Payment unspecified | 10/13/20 |
Takeda will import and distribute 50M doses of Moderna's COVID-19 vaccine, mRNA-1273, to Japan, starting in the first half of 2021 | Takeda Pharmaceutical Co. Ltd. | Japan's Ministry of Health Labour and Welfare | Payment unspecified | 10/29/20 |
Salk Institute and Bridgebio Pharma to develop therapeutics for genetically driven diseases | The Salk Institute for Biological Studies | Bridgebio Pharma Inc. | Payment unspecified | 10/21/20 |
University of Lethbridge to develop Willow Bioscience’s cannabinoids for pain, intestinal inflammation and depression | The University Of Lethbridge | Willow Biosciences Inc. | Payment unspecified | 10/8/20 |
Canadian Cancer Trials Group to evaluate the Treadwell's CFI-400945 against mCRPC | Treadwell Therapeutics | Canadian Cancer Trials Group | Payment unspecified | 10/19/20 |
Tufts Medical Center to conduct phase II clinical study for Daewoong's DWRX-2003 and oral niclosamide against COVID-19 in US | Tufts Medical Center | Daewoong Pharmaceutical Co. Ltd. | Payment unspecified | 10/26/20 |
US Government to award a contract to LabVantage Solutions to supply LIMS for COVID-19 vaccine production | U.S. Army Medical Research Acquisition Activity | Labvantage Solutions | Payment unspecified | 10/13/20 |
Univ Hospital Orebro to conduct a clinical study of Nextcell Pharma's Protrans for the treatment of type 1 diabetes in COVID-19 | Univ Hospital Orebro | Nextcell Pharma AB | Payment unspecified | 10/21/20 |
University of Campinas to conduct research on Moleculin's WP-1122 against COVID-19 | Universidade Estadual de Campina | Moleculin Biotech Inc. | Payment unspecified | 10/29/20 |
Uppsala University Hospital to conduct genetic analyses on early detection of myelodysplastic syndrome | University Hospital of Uppsala | Karolinska Institutet | Payment unspecified | 10/20/20 |
University Hospital Pilsen to conduct phase II study of Immutep's IMP-321 for the treatment of COVID-19 infection | University Hospital Pilsen | Immutep Ltd. | Payment unspecified | 10/23/20 |
Pharmather to develop and commercialize University of Arizona's ketamine for Parkinsons disease | University of Arizona | Pharmather Inc. | Payment unspecified | 10/15/20 |
Releviate Therapeutics to develop and commercialize University of California's RLVT-9-01 and RLVT-14-02 against chronic pain | University of California Riverside | Releviate Therapeutics LLC | Payment unspecified | 10/28/20 |
University of Colorado and BridgeBio to discover and advance medicines for genetic diseases | University of Colorado - Anschutz Medical Campus | Bridgebio Pharma Inc. | Payment unspecified | 10/21/20 |
University of Dundee and Almirall to identify and develop targeted protein degraders medicines for severe skin diseases | University of Dundee | Almirall Prodesfarma SA | Payment unspecified | 10/8/20 |
University of Georgia to develop Sunshine Biopharma's coronavirus protease inhibitor against COVID-19 | University of Georgia | Sunshine Biopharma Inc. | Payment unspecified | 10/19/20 |
Iksuda to sign an option agreement with University of Goettingen for worldwide rights to tumour-activated prodrug payloads | University of Gottingen | Iksuda Therapeutics Ltd. | Payment unspecified | 10/12/20 |
University of Kansas to conduct phase II clinical trial of Oxeia's OXE-103 for concussion | University of Kansas Medical Center | Oxeia Biopharmaceuticals Inc. | Payment unspecified | 10/21/20 |
Avrobio and University of Manchester to develop AVR-RD-05 for Hunter syndrome worldwide | University of Manchester | Avrobio Inc. | Payment unspecified | 10/6/20 |
Biosceptre and University of Sydney to conduct research on CAR-T cell immunotherapy for the treatment of cancer | University of Sydney | Biosceptre International Ltd. | Payment unspecified | 10/21/20 |
DNDi and the University of Tokyo to conduct phase I clinical trial of CpG-D35 in healthy adult volunteers for cutaneous leishmaniasis | University of Tokyo | Drugs for Neglected Diseases Initiative | Payment unspecified | 10/1/20 |
University of Tokyo and Eisai to research on development and drug discovery of targeted protein degradation technology | University of Tokyo | Eisai Co. Ltd. | Payment unspecified | 10/8/20 |
University of Toronto to conduct preclinical study for Sansero' low-dose psilocybin against depression and anxiety | University of Toronto | Sansero Life Sciences | Payment unspecified | 10/1/20 |
EV Biologics and Vanderbilt University to develop the extracellular vesicle (EV)-based diagnostics and therapeutics | Vanderbilt University | EV Biologics Inc. | Payment unspecified | 10/1/20 |
Vaxil to sign Cooperative Research and Development Agreement with USAMRIID to evaluate Corvax against COVID-19 infection in mouse model | Vaxil Biotherapeutics Ltd. | U.S. Army Medical Research Institute of Infectious Diseases | Payment unspecified | 10/26/20 |
LabVantage Solutions to supply its Pharma LIMS to USAMRAA’s WRAIR to support vaccine production for COVID-19 and other disease | Walter Reed Army Institute of Research | U.S. Army Medical Research Acquisition Activity | Payment unspecified | 10/13/20 |
Wellcome Sanger to use Arima's HiC technology for genomic research | Wellcome Trust Sanger Institute | Arima Genomics Inc. | Payment unspecified | 10/5/20 |
Zenith to enter CRADA with NCI to develop ZEN-3694 for multiple oncology indications including resistant ovarian cancer | Zenith Epigenetics Ltd. | National Cancer Institute | Payment unspecified | 10/5/20 |
ABL Europe to develop and manufacture University Clinic of Tuebingen's second generation COVID-19 vaccine | ABL Europe | University Clinic of Tuebingen | Payment unspecified | 11/5/20 |
Arcturus Therapeutics received new manufacturing financial support and vaccine purchases up to $220 million from the Singapore’s Economic Development Board | Arcturus Therapeutics Inc. | Singapore’s Economic Development Board | $220.00 | 11/9/20 |
AstraZeneca to conduct research on RDIF's Sputnik V vaccine in combination with its own vaccine against COVID-19 | Astrazeneca plc | Russian Direct Investment Fund | Payment unspecified | 11/23/20 |
Astrazeneca to supply COVID-19 vaccine to the Argentina Government | Astrazeneca plc | The Health Council of Investigation of the Government of Buenos Aires (Argentina) | Payment unspecified | 11/8/20 |
Baylor College to conduct phase III study to evaluate GP2 immunotherapy for the treatment of cancers including HER2 positive breast cancer | Baylor College of Medicine | Greenwich Lifesciences Inc. | Payment unspecified | 11/12/20 |
Boston Children’s Hospital and Deerfield to accelerate the development of therapies against diseases | Boston Children's Hospital | Deerfield Management Company LP | Payment unspecified | 11/10/20 |
BriaCell and NCI to sign Cooperative Research and Development Agreement to develop Bria-OTS, off-the-shelf personalized immuno-therapeutics for cancer | Briacell Therapeutics Corp. | National Cancer Institute | Payment unspecified | 11/10/20 |
Broad Institute to evaluate Ideaya's paralog CRISPR knockdown in ovarian and breast cancer patients | Broad Institute Inc. | Ideaya Biosciences Inc. | Payment unspecified | 11/12/20 |
CARE to evaluate Senhwa's Silmitasertib to treat moderate COVID-19 patients | Center for Advanced Research and Education | Senhwa Biosciences Inc. | Payment unspecified | 11/6/20 |
Actimed Therapeutics licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis from Charite-Universitatsmedizin Berlin | Charite-Universitatsmedizin Berlin | Actimed Therapeutics Ltd. | Payment unspecified | 11/23/20 |
NCI to enter CRADA to conduct non-clinical and clinical studies of Curis' CA-4948 against cancer | Curis Inc. | National Cancer Institute | Payment unspecified | 11/10/20 |
Dana-Farber and PCF to perform research on treatment against prostate cancer | Dana-Farber Cancer Institute Inc. | Prostate Cancer Foundation | Payment unspecified | 11/11/20 |
Duke University and eGenesis to perform research on in-vivo testing of pancreatic islet cell xenotransplants | Duke University School of Medicine | Egenesis Inc. | Payment unspecified | 11/5/20 |
Eli Lilly to supply bamlanivimab COVID-19 monoclonal antibody to Government of Canada | Eli Lilly and Co. Ltd. | Canadian Government | Payment unspecified | 11/24/20 |
Consortium led by Elthera to receive Eurostars grant to develop cancer therapeutics and diagnostics | Elthera AG | Eurostars | $3.16 | 11/10/20 |
Enesi and Imperial College to combine ImplaVax, saRNA and Polyplex technology to develop thermostable RNA vaccines against COVID-19 infection | Enesi Pharma Ltd. | Imperial College London | Payment unspecified | 11/18/20 |
University of Exeter and MDC to perform research and development of new therapies | Exeter University | Medicines Discovery Catapult | Payment unspecified | 11/12/20 |
Neuropathix entered a binding letter of intent with Fox Chase Chemical Diversity Center and Advanced Neural Dynamics to acquire a suite of sulfamide-containing neuroprotective compounds | Fox Chase Chemical Diversity Center Inc. | Neuropathix Inc. | Payment unspecified | 11/19/20 |
Gamaleya Research Institute of Epidemiology and Microbiology and Pharmasyntez to produce the COVID-19 Sputnik V vaccine | Gamalei Institute of Epidemiology and Microbiology | Pharmasyntez | Payment unspecified | 11/6/20 |
Generex and China CDC to develop and commercialize Ii-Key-SARS-CoV-2 coronavirus vaccine in China | Generex Biotechnology Corp. | The Chinese Centre for Disease Control and Prevention | Payment unspecified | 11/4/20 |
Geovax Labs signed a patent and biological materials license agreement with the National Institute of Allergy and Infectious Diseases in support of nonclinical development of vaccines against numerous pathogens | Geovax Labs Inc. | National Institute of Allergy and Infectious Diseases | Payment unspecified | 11/30/20 |
Harvard to conduct clinical trial of Tiziana's Foralumab alone or in combination with dexamethasone for COVID-19 infection | Harvard Medical School | Tiziana Life Sciences plc | Payment unspecified | 11/2/20 |
Harvard University to evaluate Peptron's PT-320 for Alzheimer's disease | Harvard University | Peptron Co. Ltd. | Payment unspecified | 11/27/20 |
DoD to enter CRADA with Humanigen to develop lenzilumab against COVID-19 | Humanigen Inc. | Department of Defense | Payment unspecified | 11/6/20 |
Hvivo to enter consortium with Wellcome Trust to promote development of vaccines against pathogens | Hvivo | Wellcome Trust | Payment unspecified | 11/19/20 |
Imperial College London to evaluate the efficacy of Roche’s Actemra (tocilizumab) against COVID-19 | Imperial College London | Roche Holding AG | Payment unspecified | 11/20/20 |
IVI and VITAL-Korea to sign MoU to conduct research and develop vaccine | International Vaccine Institute | Vaccine Innovative Technology Alliance Korea | Payment unspecified | 11/17/20 |
Janssen Pharmaceutical Co. and the U.S. Biomedical Advanced Research and Development Authority for the ongoing development of COVID-19 vaccine. Janssen will commit about $604M and the authority will commit about $454M to support the ongoing phase III Ensemble trial evaluating the candidate as a single dose in up to 60,000 volunteers worldwide | Janssen Pharmaceutical Co. | U.S. Biomedical Advanced Research and Development Authority | $1,058.00 | 11/16/20 |
Karolinska University Hospital to conduct phase II clinical trial for Affibody’s ABY-035 in psoriatic arthritis patients | Karolinska University Hospital | Affibody AB | Payment unspecified | 11/10/20 |
King’s College London to conduct phase II study for NM-01 against cancer | King's College London | Suzhou Nanomab Technology Ltd. | Payment unspecified | 11/5/20 |
Shionogi to conduct research and develop Kitasato Institute's antimalarial natural products | Kitasato Institute | Shionogi and Co. Ltd. | Payment unspecified | 11/25/20 |
LG Electronics and IVI to sign MOU to provide oral cholera vaccine in Ethiopia | LG Electronics Inc. | International Vaccine Institute | Payment unspecified | 11/24/20 |
Obsidian and MD Anderson to advance cytoTIL for solid tumors | MD Anderson Cancer Center | Obsidian Therapeutics Inc. | Payment unspecified | 11/18/20 |
MUSC to conduct research on Atyr Pharma's NRP-2 monoclonal antibody therapy against lung cancer | Medical University of South Carolina | Atyr Pharma Inc. | Payment unspecified | 11/12/20 |
MMV and DNDi to launch COVID-19 clinical trial in Africa | Medicines for Malaria Venture | Drugs for Neglected Diseases Initiative | Payment unspecified | 11/20/20 |
Caribou Biosciences to use MSKCC's human anti-CD371 scFvs against allogeneic cell therapies | Memorial Sloan-Kettering Cancer Center | Caribou Biosciences Inc. | Payment unspecified | 11/18/20 |
Immunoprecise Antibodies and Mila to use data and artificial intelligence to transform the way of discovering and developing novel therapeutics | Mila – Quebec Artificial Intelligence Institute | Immunoprecise Antibodies Ltd. | Payment unspecified | 11/3/20 |
Moderna to supply mRNA-1273 vaccine against COVID-19 to U.K. Government | Moderna Inc. | U.K. Government | Payment unspecified | 11/16/20 |
Moderna to supply mRNA-1273 vaccine doses to EU for the treatment of COVID-19 infection | Moderna Inc. | European Commission | Payment unspecified | 11/26/20 |
Vor Biopharma to use NCI’s CD33 CAR-T cell therapy against cancer | National Cancer Institute | Vor Biopharma Inc. | Payment unspecified | 11/11/20 |
NIAID to conduct phase I study of NeoImmuneTech's NT-I7 in adults with mild COVID-19 | National Institute of Allergy and Infectious Diseases | Neoimmunetech Inc. | Payment unspecified | 11/30/20 |
NSPO and Grifols to form a joint venture to boost plasma-derived medicines self-sufficiency in the Middle East, Egypt and Africa | National Service Projects Organization | Grifols SA | Payment unspecified | 11/24/20 |
Daiichi and NSABP to conduct DESTINY-Breast05 phase III trial of ENHERTU versus T-DM1 in HER2 positive early breast cancer | National Surgical Adjuvant Breast and Bowel Project Foundation | Daiichi Sankyo Co. Ltd. | Payment unspecified | 11/2/20 |
Novavax to supply NVX-CoV2373 against COVID-19 to Australian Government | Novavax Inc. | Australian Government | Payment unspecified | 11/4/20 |
NYU Langone Health to conduct COVID-19 clinical trial for AstraZeneca’s ChAdOx1 nCoV-19 | NYU Langone Health | Astrazeneca plc | Payment unspecified | 11/11/20 |
Pfizer to supply 8M doses of BNT-162b2 to Government of Israel for the treatment of COVID-19 infection | Pfizer Inc. | Government of Israel | Payment unspecified | 11/13/20 |
Duchesnay to develop and commercialize Population Council's ANNOVERA for contraception in the US | Population Council | Duchesnay Inc. | Payment unspecified | 11/30/20 |
TopRidge Pharma to develop and commercialize RDIF's Sputnik-V in mainland China, Hong Kong, Mocau and Taiwan | Russian Direct Investment Fund | Topridge Pharma Ltd. | $921.00 | 11/12/20 |
Ivy Brain to conduct phase 0 clinical trial of BeiGene's pamiparib in patients with diagnosed and recurrent glioblastoma | The Ivy Brain Tumor Center | Beigene Co. Ltd. | Payment unspecified | 11/16/20 |
Umea University and Double Bond to study use of iron succinate in patients with heart failure and iron deficiency | Umea University | Double Bond Pharmaceutical AB | Payment unspecified | 11/20/20 |
Decibel to use University of Florida's IP related to AAV-mediated gene therapy technology to develop DB-OTO for congenital hearing loss | University of Florida | Decibel Therapeutics Inc. | Payment unspecified | 11/2/20 |
UMSOM to investigate Gain Therapeutics' structurally targeted allosteric regulators in cellular models of Gaucher disease and Parkinson’s disease | University of Maryland School of Medicine | Gain Therapeutics SA | Payment unspecified | 11/30/20 |
Ascentage to develop University of Michigan's MDM2 protein degrader developed using Proteolysis-Targeting Chimeras technology against cancer worldwide | University of Michigan | Ascentage Pharma Group Corp. Ltd. | Payment unspecified | 11/29/20 |
University of Oxford and Evox to develop exosome therapies for rare diseases | University of Oxford | Evox Therapeutics Ltd. | Payment unspecified | 11/17/20 |
University of Pennsylvania to develop casirivimab and imdevimab cocktail AAV vectors for COVID-19 | University of Pennsylvania | Regeneron Pharmaceuticals Inc. | Payment unspecified | 11/30/20 |
University of Pennsylvania to study use of Neuraly's NLY-01 to therapeutically target a neuroinflammatory mechanism of glaucoma | University of Pennsylvania | Neuraly Inc. | Payment unspecified | 11/10/20 |
University of Sydney to conduct a second clinical study of Dimerix' DMX-200 against COVID-19 | University of Sydney | Dimerix Bioscience Pty Ltd. | Payment unspecified | 11/30/20 |
Uppsala University to evaluate Nextcell's Protrans for the treatment of children and adolescents with type I diabetes | Uppsala University | Nextcell Pharma AB | Payment unspecified | 11/16/20 |
Weill Cornell Medicine and Biohaven to initiate proof of concept trial with CGRP receptor antagonist in plaque psoriasis | Weill Cornell Medicine | Biohaven Pharmaceutical Holding Co. Ltd. | Payment unspecified | 11/16/20 |
Apeloa and Zhejiang University to develop therapeutics | Zhejiang University of Technology | Apeloa Pharmaceutical Co. Ltd. | Payment unspecified | 11/23/20 |
Amgen to grant rights of AMG-634 for tuberculosis and erythema nodosum leprosum to Medicines Development for Global Health | Amgen Inc. | Medicines Development for Global Health | Payment unspecified | 12/22/20 |
Anixa Biosciences to acquire licensing rights to an ovarian cancer vaccine technology worldwide from Cleveland Clinic | Anixa Biosciences Inc. | Cleveland Clinic | Payment unspecified | 12/1/20 |
CEPI partners and Biological E to advance the development and manufacture of COVID-19 vaccine | Biological E Ltd. | Coalition for Epidemic Preparedness Innovations | $5.00 | 12/29/20 |
Biontech to supply U.S. Government with additional doses of mRNA-based vaccine, BNT-162 against COVID-19 | Biontech SE | U.S. Department of Health and Human Services | $1,950.00 | 12/23/20 |
Cancer Research UK to conduct a phase Ib/IIa clinical study of Teon Therapeutics' TT-702 against cancer including prostate cancer | Cancer Research UK | Teon Therapeutics Inc. | Payment unspecified | 12/14/20 |
Cleveland Clinic Taussig Cancer Center to investigate Rafael Pharmaceuticals' CPI-613 Clear Cell Sarcoma | Cleveland Clinic Taussig Cancer Center | Rafael Pharmaceuticals Inc. | Payment unspecified | 12/1/20 |
Oryzon Genomics and Columbia University to study the effects of LSD1 inhibitors in preclinical Setd1a models | Columbia University | Oryzon Genomics SA | Payment unspecified | 12/17/20 |
Amgen and Biotechnology Development Center to develop next-generation bispecific antibody drugs | Development Center for Biotechnology | Amgen Inc. | Payment unspecified | 12/8/20 |
Diamyd Medical and Critical Path Institute to develop advanced drug development tools for type I diabetes | Diamyd Medical AB | Critical Path Institute | Payment unspecified | 12/16/20 |
Eli Lilly and Unitedhealth to conduct a pragmatic study of bamlanivimab in high-risk COVID-19 affected patients | Eli Lilly and Co. | Unitedhealth Group Inc. | Payment unspecified | 12/4/20 |
Pierre Fabre to develop and commercialize EspeRare's ER-004 for XLHED worldwide including Europe and the US | Esperare Foundation | Pierre Fabre Group | Payment unspecified | 12/9/20 |
Sterotherapeutics to sign cooperative research and development agreement with NICHD to develop a treatment for Cushing Syndrome patients | Eunice Kennedy Shriver National Institute of Child Health and Human Development | Sterotherapeutics LLC | Payment unspecified | 12/2/20 |
EBRIS to evaluate 9 Meters Biopharma's larazotide against COVID-19 respiratory complication | European Biomedical Research Institute of Salerno | 9 Meters Biopharma Inc. | Payment unspecified | 12/21/20 |
Evofem to supply Phexxi to U.S. Department of Veterans Affairs for female contraception | Evofem Biosciences Inc. | U.S. Department of Veterans Affairs | Payment unspecified | 12/3/20 |
Glycostem Therapeutics and Ghent University to sign license agreement for NK cell production technology | Ghent University | Glycostem Therapeutics BV | Payment unspecified | 12/17/20 |
University of Pennsylvania and Gyroscope Therapeutics to create gene therapies for serious eye diseases which could lead to permanent vision loss | Gyroscope Therapeutics Ltd | University of Pennsylvania | Payment unspecified | 12/18/20 |
University of Pennsylvania and Gyroscope Therapeutics to create gene therapies for serious eye diseases | Gyroscope Therapeutics Ltd. | University of Pennsylvania | Payment unspecified | 12/18/20 |
Immunoprecise and Radboudumc to develop therapeutic nanomedicine and diagnostics against COVID-19 | Immunoprecise Antibodies Ltd. | Radboud University Medical Center Nijmegen | Payment unspecified | 12/30/20 |
IVI to sign memorandum of understanding for the clinical development of Eubiologics' COVID-19 vaccine against COVID-19 | International Vaccine Institute | Eubiologics Co. Ltd. | Payment unspecified | 12/3/20 |
Janssen Pharmaceuticals to supply COVID-19 vaccine to Gavi | Janssen Pharmaceutica NV | Gavi, The Vaccine Alliance | Payment unspecified | 12/18/20 |
NorthShore and Johns Hopkins Medicine to test the effectiveness of convalescent blood plasma for COVID-19 | Johns Hopkins Medicine | NorthShore University HealthSystem (NorthShore) | Payment unspecified | 12/8/20 |
GAVI to purchase 500M doses of JNJ-78436735 from Johnson & Johnson | Johnson & Johnson Inc. | Global Alliance for Vaccines and Immunization | Payment unspecified | 12/18/20 |
Kanazawa University to conduct phase I clinical trial of Telix’s TLX591-CDx for the imaging of prostate cancer using positron emission tomography | Kanazawa University | Telix Pharmaceuticals Japan K.K. | Payment unspecified | 12/14/20 |
Korea University Guro Hospital to conduct phase I/IIa of Geneone's GLS-5310 for the treatment of COVID-19 infection | Korea University Guro Hospital | Geneone Life Science Inc. | Payment unspecified | 12/18/20 |
Mainz University Hospital to conduct phase III study of CureVac's CVnCoV against COVID-19 infection | Mainz University Hospital | Curevac AG | Payment unspecified | 12/21/20 |
Radius Health and MGH to discover and research small molecules for musculoskeletal diseases, with an option to license intellectual property | Massachusetts General Hospital | Radius Health Inc. | Payment unspecified | 12/15/20 |
Celcuity and Massachusetts General Hospital to conduct a phase II trial evaluating the efficacy and safety of Puma's Nerlynx (neratinib) and Faslodex (fulvestrant) in previously treated metastatic HR-positive, HER2-negative breast cancer patients selected with Celsignia HER2 Activity Test | Massachusetts General Hospital | Celcuity Inc. | Payment unspecified | 12/23/20 |
MD Anderson to conduct phase II combination studies on ImmunoGenesis' evofosfamide with checkpoint blockade for solid tumor hypoxia | MD Anderson Cancer Center | Immunogenesis Inc. | Payment unspecified | 12/9/20 |
NIHE to enter into a memorandum of agreement to initiate clinical trials of Medigen's MVC-COV1901 against COVID-19 in Vietnam | Medigen Vaccine Biologics Corp | National Institute of Hygiene and Epidemiology, Vietnam | Payment unspecified | 10/30/20 |
Merck to supply MK-7110 to the U.S. Government for COVID-19 | Merck & Co. Inc. | U.S. Government | $356.00 | 12/23/20 |
Nanogen and Military Medical Academy to conduct clinical trial on COVID-19 vaccine in Vietnam | Military Medical Academy | Nanogen Biopharmaceutical Co. | Payment unspecified | 12/10/20 |
Korean Ministry of Health to support Future Medicine’s nucleosides based COVID-19 therapy | Ministry of Health, Welfare and Family Affairs | Future Medicine Co. Ltd. | Payment unspecified | 12/22/20 |
Moderna to supply mRNA-1273 vaccine against Covid-19 to Ministry of Health of Singapore | Moderna Inc. | Ministry of Health, Singapore | Payment unspecified | 12/14/20 |
Moderna Therapeutics to supply additional doses of mRNA-1273 for COVID-19 infection to U.S. Department of Defense | Moderna Inc. | U.S. Department of Defense | $1,970.00 | 12/29/20 |
Moderna to supply mRNA-1273 vaccine against COVID-19 to Republic of Korea government in South Korea | Moderna Inc. | Republic of Korea Government | Payment unspecified | 12/31/20 |
Immuron and Monash University to advance SARS-CoV-2 findings and to further research and identify inhibitory substances in Immuron’s marketed products | Monash University | Immuron Ltd. | Payment unspecified | 12/15/20 |
Chinook Therapeutics to acquire IP rights related to methods and compositions from Morehouse School of Medicine against kidney diseases worldwide | Morehouse School Of Medicine | Chinook Therapeutics Inc | Payment unspecified | 12/8/20 |
Nagoya University and LUCA Science to conduct joint research and develop mitochondrial therapy for cardiac ischemic–reperfusion injury | Nagoya University Graduate School of Medicine | Luca Science Inc. | Payment unspecified | 12/1/20 |
NIH to grant CCR7 homing receptor rights to ONK for use in ONKT-101 to treat relapsed/refractory B cell malignancies | National Institutes of Health | ONK Therapeutics Ltd. | Payment unspecified | 12/17/20 |
Immunoprecise and NRC to develop neutralizing Polytope antibodies against SARS-CoV-2 | National Research Council of Canada | Immunoprecise Antibodies Ltd. | Payment unspecified | 12/11/20 |
AcelRx Pharmaceuticals and NRHA to develop and promote DSUVIA against pain | National Rural Health Association | AcelRx Pharmaceuticals Inc | Payment unspecified | 12/4/20 |
New Zealand Government to purchase Novavax's NVX-CoV2373 for the treatment of COVID-19 infection | Novavax Inc. | New Zealand Government | Payment unspecified | 12/16/20 |
Kazia Therapeutics to sign LOI with PNOC for Paxalisib combination study in diffuse intrinsic pontine glioma | Pacific Pediatric Neuro-Oncology Consortium | Kazia Therapeutics Ltd | Payment unspecified | 12/10/20 |
4D Pharma and PPMI to study and to develop treatments for Parkinson’s disease | Parkinson’s Progression Markers Initiative | 4D pharma plc | Payment unspecified | 12/18/20 |
Rheos to use Patientslikeme's database of proteomic, metabolomic, transcriptomic and genetic data from patients to identify novel targets for treating immune-mediated diseases | Patientslikeme LLC | Rheos Medicines Inc. | Payment unspecified | 12/17/20 |
PWSA to conduct clinical trial for Harmony's pitolisant against excessive daytime sleepiness in PWS patients | Prader-Willi Syndrome Association USA | Harmony Biosciences LLC | Payment unspecified | 12/15/20 |
Barer Institute to acquire technology and related intellectual property from Princeton University for SHMT inhibitor worldwide | Princeton University | Barer Institute | Payment unspecified | 12/22/20 |
RXN to conduct clinical trial of Organicell's Zofin for the treatment of HFpEF associated with COVID-19 infection | Regenerative Care Network | Organicell Regenerative Medicine | Payment unspecified | 10/20/20 |
RDIF to supply Sputnik V vaccine to Ministry of Health of Kazakhstan against COVID-19 | Russian Direct Investment Fund | Ministry of Health, Kazakhstan | Payment unspecified | 12/4/20 |
RDIF to supply Sputnik V against COVID-19 to Government of Argentina in Argentina | Russian Direct Investment Fund | Government of Argentina | Payment unspecified | 12/10/20 |
RDIF to supply Sputnik V against COVID-19 to Government of Serbia in Serbia | Russian Direct Investment Fund | Government of Serbia | Payment unspecified | 12/30/20 |
The Russian Direct Investment Fund, the Gamaleya National Center, Astrazeneca and R-Pharma to assess the immunogenicity and safety of the combined use of one of the components of the Sputnik V vaccine and one of the components of the AZD-1222 vaccine | Russian Direct Investment Fund | Gamaleya National Center | Payment unspecified | 12/22/20 |
Sara’s Cure to conduct phase II study of Rafael's CPI-613 in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue | Sara’s Cure | Rafael Pharmaceuticals Inc. | Payment unspecified | 12/1/20 |
SNUH to conduct phase I clinical trial on SK bioscience's NBP-2001 for COVID-19 | Seoul National University Hospital | SK Bioscience | Payment unspecified | 12/2/20 |
Sidney Kimmel to develop Lantern's LP-184 in glioblastoma multiforme | Sidney Kimmel Comprehensive Cancer Center | Lantern Pharma Inc. | Payment unspecified | 12/17/20 |
Circuit Clinical and CIGBS to perform clinical research for prevention and treatment of SARS-CoV-2 | The Center for Integrated Global Biomedical Sciences | Circuit Clinical | Payment unspecified | 12/17/20 |
Sean M Healey to conduct phase IIb/III study of Seelos' SLS-005 against amyotrophic lateral sclerosis | The General Hospital Corp. | Seelos Therapeutics Inc. | Payment unspecified | 12/15/20 |
The Ivy Brain Tumor Center to conduct first-in-human clinical trial for Sonalasense's aminolevulinic acid sonodynamic therapy in recurrent glioblastoma multiforme | The Ivy Brain Tumor Center | Sonalasense Inc. | Payment unspecified | 12/14/20 |
Undisclosed institutions to conduct pragmatic study for Eli Lilly's bamlanivimab against COVID-19 in New Mexico | Undisclosed Institutions | Eli Lilly and Co. | Payment unspecified | 12/18/20 |
Maastricht University and Silo Pharma to investigate the low doses of psilocybin and LSD against Parkinson’s disease | Universiteit Maastricht | Silo Pharma Inc. | Payment unspecified | 12/2/20 |
University Hospital of Cologne to conduct phase I/IIa of DZIF-10c for the treatment of COVID-19 infection | University Hospital of Cologne | Boehringer Ingelheim International GmbH | Payment unspecified | 12/21/20 |
Eyam Vaccines and Immunotherapeutics entered a license agreement with the University of British Columbia for the commercialization of several unique COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform | University of British Columbia | Eyam Vaccines and Immunotherapeutics Inc. | Payment unspecified | 12/7/20 |
Therapix and University of Calgary to develop THX-160 for pain | University of Calgary | Therapix Biosciences Ltd. | Payment unspecified | 12/2/20 |
Global Cancer Technology licensed technology from the University of California San Diego Medical System for a novel treatment to selectively target and inactivate coronavirus virions | University of California San Diego | Global Cancer Technology Inc. | Payment unspecified | 12/31/20 |
UCSF and BridgeBio Pharma to advance the development of therapeutics against genetic diseases | University of California San Francisco | Bridgebio Pharma Inc. | Payment unspecified | 12/23/20 |
Tonix to use University of Geneva's technology for the oxytocin based programs including TNX-1900 against insulin resistance related syndromes, including obesity in the US, Europe | University of Geneva | Tonix Pharmaceuticals Holding Corp. | Payment unspecified | 12/22/20 |
CaaMTech and UMass Dartmouth to perform research on psychedelic tryptamines | University of Massachusetts | Caamtech LLC | Payment unspecified | 12/9/20 |
CN Bio and the University of Melbourne to advance therapies for respiratory complications in recovered Covid-19 patients | University of Melbourne | CN Bio Innovations Ltd. | Payment unspecified | 12/15/20 |
University of Nebraska and ZEA to develop plant-based anti-inflammatories | University of Nebraska | ZEA Biosciences | Payment unspecified | 12/1/20 |
University of Texas to conduct phase II study of Clene's CNM-Au8 against MS and PD | University of Texas Southwestern Medical Center | Clene Nanomedicine Inc. | Payment unspecified | 12/30/20 |
Ilya Pharma extended its immunophysiology and synthetic biology research agreement with Uppsala University to accelerate development of Ilya’s pipeline of advanced therapies based on modified lactic acid bacteria expressing human chemokines beyond acute skin wounds to diabetic wounds and inflammatory bowel disease | Uppsala University | Ilya Pharma AB | Payment unspecified | 12/22/20 |
Vanderbilt University to develop Ampio’s Ampion in inflammatory kidney diseases | Vanderbilt University Medical Center | Ampio Pharmaceuticals Inc. | Payment unspecified | 12/10/20 |
VIB and TIB to form a joint venture, TV-SynBio to conduct research on synthetic biology and biosynthesis of natural plant products | VIB | Tianjin Institute Of Industrial Biotechnology | Payment unspecified | 12/9/20 |
Illumina and Weill Cornell to sequence the complete human genomes of patients to find unidentified therapies for the genomic alterations | Weill Cornell Medicine | Illumina Inc. | Payment unspecified | 12/3/20 |
Yale University to evaluate Bioxcel Therapeutics’ BXCL-501 in post-traumatic stress disorder patients | Yale University | Bioxcel Therapeutics Inc. | Payment unspecified | 12/7/20 |